

(51) International Patent Classification:

A61K 9/08 (2006.01) A61P 7/04 (2006.01)
A61K 48/00 (2006.01) A61K 47/02 (2006.01)
A61K 47/26 (2006.01) A61K 47/10 (2017.01)

(21) International Application Number:

PCT/US2021/064222

(22) International Filing Date:

17 December 2021 (17.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/127,826 18 December 2020 (18.12.2020) US

(71) Applicants: SANGAMO THERAPEUTICS, INC.
[US/US]; 7000 Marina Boulevard, Brisbane, California
94005 (US). PFIZER INC. [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: CONNER, Jessica Eileen; c/o Pfizer Inc.,
875 Chesterfield Parkway West, Chesterfield, Missouri
63017 (US). CRAWFORD, Lindsey Anne; c/o Pfizer
Inc., 1 Burt Road, Andover, Massachusetts 01801
(US). DAMITZ, Robert; c/o Sangamo Therapeutics, Inc.,
7000 Marina Boulevard, Brisbane, California 94005 (US).
DAVIS, Brendan Michael; c/o Pfizer Inc., 1 Burt Road,
Andover, Massachusetts 01810 (US). HODGE, Cody
Michael; c/o Pfizer Inc., 875 Chesterfield Parkway West,
Chesterfield, Missouri 63017 (US). KIMMEL II, Michael
Leland; c/o Pfizer Inc., 875 Chesterfield Parkway West,
Chesterfield, Missouri 63017 (US). QURESHI WIL-
LARD, Tihami; c/o Pfizer Inc., 875 Chesterfield Park-
way West, Chesterfield, Missouri 63017 (US). RAMSEY,
Phillip; c/o Sangamo Therapeutics, Inc., 7000 Marina
Boulevard, Brisbane, California 94005 (US). THORNE,
Daniel Joseph; c/o Pfizer Inc., 875 Chesterfield Parkway
West, Chesterfield, Missouri 63017 (US). YOUNG, An-
thony Lee; c/o Pfizer Inc., 875 Chesterfield Parkway West,
Chesterfield, Missouri 63017 (US).

(74) Agent: LI, Z. Ying et al.; Steptoe & Johnson LLP, 1330
Connecticut Avenue, N.W., Washington, District of Colum-
bia 20036 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR

(57) Abstract: The present invention provides compositions comprising a recombinant AAV and one or more pharmaceutically ac-
ceptable excipients. The compositions have improved stability and shelf life as compared to other AAV compositions.

WO 2022/133324 A1

IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority from U.S. Application No. 63/127,826, filed December 18, 2020, the content of which is incorporated by reference herein in its entirety.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on December 1, 2021, is named 025297_WO029_SL.txt and is 19,967 bytes in size.

BACKGROUND OF THE INVENTION

[0003] Gene therapy is a promising approach to treat genetic diseases. It introduces a healthy copy of the defective gene to the patient, or inactivates a mutated gene that is functioning improperly. A genetic disease that is of particular interest for gene therapy research is hemophilia A. Hemophilia A, also called classic hemophilia, is a X-linked genetic disease in which the blood clotting process is impaired due to a missing or defective gene encoding factor VIII. Patients with hemophilia A can bleed internally (e.g., into joints and muscles) or externally (e.g., due to minor cuts, trauma, or dental procedures). Normal plasma levels of factor VIII range from 50% to 100%. Mild hemophilia A is characterized by a level of 6% to 49% of factor VIII in the blood; patients typically bleed only after serious injury, trauma, or surgery. Moderate hemophilia A is characterized by a level of 1% to 5% of factor VIII in the blood; patients have bleeding episodes after injuries. Severe hemophilia A is characterized by a level of less than 1% of factor VIII in the blood; patients experience bleeding after injuries and also have frequent spontaneous bleeding episodes, often in their joints and muscles. *See also* the website of the National Hemophilia Foundation. Hemophilia A is commonly treated on-demand (upon

bleeding) or prophylactically with replacement factor VIII. Some patients develop alloantibodies (aka inhibitors) against the replacement factor, rendering the therapy ineffective. Current therapies are burdensome because they require frequent intravenous injections and also are limited by resources in developing countries. Thus, gene therapy offers a promising approach to treating hemophilia A.

[0004] Recombinant adeno-associated virus (rAAV) has been explored as a platform for gene delivery in gene therapy. Adeno-associated virus (AAV) is a small non-enveloped virus belonging to the family *Parvoviridae* and the genus *Dependoparvovirus*. The virus is composed of a single-stranded DNA genome packaged into capsids assembled from three capsid proteins – viral protein (VP) 1, VP2, and VP3. Formulating rAAV preparations into pharmaceutical compositions for clinical use has been a challenge. Commonly used rAAV formulations have been observed to form visible precipitates over time or during lab-simulated stress tests. Left unaddressed, these precipitates represent a risk to patient safety. Physical stability issues observed with some rAAV formulations also could negatively impact the efficacy of products over the shelf life required for storage, shipment, and administration to patients (*see, e.g., Wright et al., Molecular Therapy* (2005) 12(1):171-8; Croyle et al., *Gene Therapy* (2001) 8:1281-90). Thus, there is a need for developing improved formulations for rAAV vectors so that their therapeutic potential in gene therapy can be fully implemented.

SUMMARY OF THE INVENTION

[0005] The present disclosure provides stable rAAV vector formulations suitable for clinical administration. In an aspect, the disclosure provides a pharmaceutical composition comprising an rAAV vector, sodium chloride (NaCl), potassium chloride (KCl), disodium phosphate (Na_2HPO_4), monopotassium phosphate (KH_2PO_4), magnesium chloride (MgCl_2), a polyol (e.g., sucrose), and a poloxamer (e.g., poloxamer 188), optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and has a pH of about 7.1 to about 7.5.

[0006] In some embodiments, the composition contains about 0.1 to about 2.0 mM (e.g., about 0.5 mM or higher, about 1.3 mM or higher, or about 1.4 mM) magnesium chloride.

[0007] In some embodiments, the composition contains about 150 to about 200 mM, optionally about 172 mM, sodium chloride.

[0008] In some embodiments, the composition contains about 2.5 to about 3.0 mM, optionally about 2.7 mM, potassium chloride.

[0009] In some embodiments, the composition contains about 5 to about 10 mM, optionally about 8 mM, disodium phosphate.

[0010] In some embodiments, the composition contains about 1.0 to about 2.0 mM, optionally about 1.5 mM, monopotassium phosphate.

[0011] In some embodiments, the composition contains about 0.5% to about 2% (w/v), optionally about 1% (w/v), sucrose.

[0012] In some embodiments, the composition contains about 0.01% to about 0.1% (w/v), optionally about 0.05% (w/v), poloxamer 188.

[0013] In particular embodiments, the present disclosure provides a pharmaceutical composition comprising an rAAV vector, about 171.81 mM sodium chloride, about 2.68 mM potassium chloride, about 8.10 mM disodium phosphate, about 1.47 mM monopotassium phosphate, about 1.40 mM magnesium chloride, about 1.00% (w/v) sucrose, and about 0.05% (w/v) poloxamer 188, optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and has a pH of about 7.1 to about 7.5.

[0014] In other particular embodiments, the present disclosure provides a pharmaceutical composition comprising an rAAV vector, about 172 mM sodium chloride, about 2.68 mM potassium chloride, about 8.10 mM disodium phosphate, about 1.47 mM monopotassium phosphate, about 0.49 mM magnesium chloride, about 1.00% (w/v) sucrose, and about 0.05% (w/v) poloxamer 188, optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and has a pH of about 7.1 to about 7.5.

[0015] In some embodiments, the rAAV in the present compositions comprises a genome comprising an expression cassette for a therapeutic protein, such as a human factor VIII polypeptide (e.g., SEQ ID NO:1). In particular embodiments, the AAV genome comprises SEQ ID NO:2 or nucleotides 131-5,024 of SEQ ID NO:2.

[0016] In some embodiments, the composition contains the rAAV at about $1.0\text{E}+12$ to about $1.0\text{E}+14$ vector genomes (vg) per mL, optionally about $1.0\text{E}+13$ to about $5.0\text{E}+13$ vg per mL (e.g., about $1.0\text{E}+13$ vg per mL).

[0017] In some embodiments, the rAAV comprises an AAV6 capsid protein (e.g., having an AAV6 capsid). In some embodiments, the AAV genome comprises inverted terminal repeats (ITR) from AAV2.

[0018] In another aspect, the present disclosure provides a vial comprising 5-10 mL, optionally 6.4 mL, of the present composition. The vial may be made of, e.g., cyclo-olefin copolymer, and/or may have an in-place thermoplastic elastomer stopper.

[0019] In another aspect, the present disclosure provides a method of treating a patient in need of a therapeutic protein, comprising administering to the patient the present composition. In some embodiments, the present disclosure provides a method of increasing the serum level of factor VIII in a human subject in need thereof (e.g., a human subject having hemophilia A), comprising administering intravenously to the human subject the present composition where the rAAV encodes a human factor VIII polypeptide. Also provided are the pharmaceutical compositions for use in such treatment methods, and the use of the compositions for the manufacture of a medicament for use in such methods.

[0020] Other features, objects, and advantages of the invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments and aspects of the invention, is given by way of illustration only, not limitation. Various changes and modification within the scope of the invention will become apparent to those skilled in the art from the detailed description.

BRIEF DESCRIPTION OF THE FIGURES

[0021] **FIGs. 1A-F** summarize the characterization of the particulate matter found in samples of formulations containing SB-525.

[0022] **FIG. 2** shows a schematic of buffer exchange by tangential flow filtration (TFF).

[0023] **FIG. 3** shows the formulation, fill, and finish steps for the AAV6 vector formulations.

[0024] **FIG. 4A** shows the vector genome (vg) titer and infectious titer of AAV6 vector formulations following multiple freeze thaw cycles. Error bars displayed are either $\pm$ the percentage RSD from $N \geq 3$ sample measurements for particle concentration by MADLS, or $\pm$ the accepted test variability for vg titer, median tissue culture infectious dose (TCID₅₀), ELISA, and SE-LC. RSD: relative standard deviation. MADLS: multi-angle dynamic light scattering. SE-LC: size exclusion liquid chromatography.

[0025] **FIG. 4B** shows the capsid titer and particle concentration of AAV6 vector formulations following multiple freeze/thaw cycles. Error bars displayed are either $\pm$ the percentage RSD from $N \geq 3$ sample measurements for particle concentration by MADLS, or $\pm$ the accepted test variability for vg titer, TCID₅₀, ELISA, and SE-LC.

[0026] **FIG. 4C** is a table showing the general and purity quality attribute results of freeze/thaw AAV6 vector formulation samples.

[0027] **FIG. 4D** is a table showing the strength quality attribute results of freeze/thaw AAV6 vector formulation samples.

[0028] **FIG. 5A** shows vg and infectious titer over up to 6 months at ambient (25°C/60% RH) conditions. RH: relative humidity.

[0029] **FIG. 5B** shows capsid titer and particle concentration over up to 6 months at ambient (25°C/60% RH) conditions.

[0030] **FIG. 5C** is a table showing the general and purity quality attribute results of ambient (25°C/60% RH) incubated samples. ND: no data. NAA: no analysis available.

[0031] **FIG. 5D** is a table showing the strength quality attribute results of ambient (25°C/60% RH) incubated samples.

[0032] **FIG. 6A** shows vg and infectious titer over 3 months at stressed (40°C/75% RH) conditions.

[0033] **FIG. 6B** shows capsid titer and particle concentration over up to 7 months at stressed (40°C/75% RH) conditions.

[0034] **FIG. 6C** is a table showing the general and purity quality attribute results of stressed (40°C/75%RH) incubated samples.

[0035] **FIG. 6D** is a table showing the strength quality attribute results of stressed (40°C/75% RH) incubated samples.

[0036] **FIG. 7** is a table showing quality attribute with associated and failure criteria for stability samples.

[0037] **FIG. 8** is a table showing the inter-sample formulation assessment summary.

[0038] **FIG. 9** is a table showing the study endpoint trendline and formulation assessments for general and purity quality attributes.

[0039] **FIG. 10** is a table showing the long term (24 month) stability of the SB-525 drug product at the intended storage temperature (-70°C).

DETAILED DESCRIPTION OF THE INVENTION

[0040] The present disclosure provides pharmaceutical compositions comprising AAV vectors and one or more pharmaceutically acceptable excipients. The present AAV vector compositions may comprise rAAV whose genome carries an expression cassette for a protein of interest (e.g., a therapeutic protein). The present inventors have unexpectedly discovered that AAV vector formulations that are essentially calcium free (e.g., having no added calcium in the formulation) have improved stability and shelf life as compared to prior composition. Calcium is typically included in prior formulations due to the conventional belief that calcium would improve the stability of AAV compositions (*see, e.g.,* Turnbull et al., *Hum Gene Ther.* (2000) 11(4):629-35; Cotmore et al., *J Virol.* (2010) 84(4):1945-56). The inventors have discovered that the present AAV vector compositions have improved appearance (e.g., clarity and lack of color), more stable pH, and less aggregates (as determined by product quality attributes under freeze/thaw cycles and accelerated stability conditions). Because the AAV vector product formulated without calcium has demonstrated better product stability, calcium ions are not required for product performance or stability.

I. Preparation of Recombinant AAV

[0041] The viral preparations described herein may be obtained by any known production systems, such as mammalian cell AAV production systems (e.g., those based on 293T or HEK293 cells) and insect cell AAV production systems (e.g., those based on sf9 insect cells and/or those using baculoviral helper vectors). The viral preparations may be purified from the cell cultures by using well known techniques such as discontinuous cesium chloride density gradients (*see, e.g.,* Grieger, *Mol Ther Methods Clin Dev.* (2016) 3:16002).

[0042] The present compositions may comprise AAV of any or a combination of a variety of AAV serotypes, such as AAV1, AAV2, AAV3, AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV8.2, AAV9, AAVrh10, AAV10, and AAV11, as well as variants, hybrids, chimera or pseudo-types thereof. By “pseudo-typed” or “cross-packaged” rAAV is meant a recombinant AAV whose capsid is replaced with the capsid of another AAV serotype, to, for example, alter transduction efficacy or tropism profiles of the virus (*see, e.g.,* Balaji et al., *J Surg Res.* (2013) 184(1):691-8). By “chimeric” or “hybrid” rAAV is meant a recombinant AAV whose capsid is

assembled from capsid proteins derived from different serotypes and/or whose capsid proteins are chimeric proteins with sequences derived from different serotypes (e.g., serotypes 1 and 2; *see, e.g.*, Hauck et al., *Mol Ther.* (2003) 7(3):419-25). For example, the present compositions may comprise recombinant AAV whose genome such as the ITRs is derived from one serotype such as AAV2 while the capsids are derived from another serotype; e.g., AAV2/8, AAV2/5, AAV2/6, AAV2/9, or AAV2/6/9. *See, e.g.*, U.S. Pats. 7,198,951 and 9,585,971.

II. Formulation of Recombinant AAV

[0043] Once purified, the AAV preparations can be formulated as described herein, for example, by buffer exchange through tangential flow filtration, normal flow filtration using stir-cells, gel filtration, dialysis, column chromatography, and/or desalting columns, to arrive at a composition comprising the desired ingredients. By way of illustration, the purified viral preparation may be concentrated first by ultrafiltration (UF) and then diafiltrated (DF) with 10 times or more equivalent volumes of the desired aqueous formulation solution. *See also* the Examples below.

[0044] The formulation solution may comprise tonicity agents, stabilizing agents, surfactants, and buffering agents. Buffering agents may include, for example, acetate, succinate (e.g., disodium succinate hexahydrate), succinic acid, gluconate, citrate, histidine, acetic acid, phosphate, phosphoric acid, ascorbate, ascorbic acid, tartaric acid, malate, maleic acid, glycine, lactate, lactic acid, bicarbonate, carbonic acid, sodium benzoate, benzoic acid, edetate, imidazole, tris, and mixtures thereof. In some embodiments, the formulation solution contains sodium chloride and/or potassium chloride at, e.g., about 150-200 mM (e.g., about 150 mM, about 155 mM, about 160 mM, about 165 mM, about 168 mM, about 170 mM, about 171 mM, about 171.1 mM, about 171.2 mM, about 171.3 mM, about 171.4 mM, about 171.5 mM, about 171.6 mM, about 171.7 mM, about 171.8 mM, about 171.9 mM, or about 172 mM) and about 2.5-3.0 mM (e.g., about 2.5 mM, about 2.6 mM, about 2.61 mM, about 2.61 mM, about 2.63 mM, about 2.64 mM, about 2.65 mM, about 2.66 mM, about 2.67 mM, about 2.68 mM, about 2.69 mM, or about 2.7 mM, about 2.8 mM, about 2.9 mM, about 3.0 mM), respectively.

[0045] The formulation solution may be phosphate-buffered, e.g., by disodium phosphate and/or monopotassium phosphate. In some embodiments, the total phosphate ion concentration in the formulation solution is about 8-12 mM (e.g., about 9.6 mM or about 9.57 mM). In certain

embodiments, the formulation solution contains about 5-10 mM (e.g., about 5 mM, about 6 mM, about 7 mM, about 7.9 mM, about 8 mM or about 8.1 mM, about 8.2 mM, about 8.5 mM, about 9 mM, or about 10 mM) disodium phosphate and about 1-2 mM (e.g., about 1 mM, about 1.2 mM, about 1.3 mM, about 1.45 mM, about 1.47 mM, about 1.48 mM, about 1.49 mM, about 1.5, about 1.6 mM, about 1.7 mM, about 1.8 mM, about 1.9 Mm, or about 2 mM) monopotassium phosphate. The formulation may have a pH of about 6.5-8.0 (e.g., about 7.1-7.5, about 7.1, about 7.2, about 7.3, about 7.4, or about 7.5).

[0046] The formulation solution may contain magnesium but no added calcium. In some embodiments, the formulation solution contains about 0.1 to 2.0 mM (e.g., about 0.5 to about 1.4 mM, about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.42 mM, about 0.44 mM, about 0.45 mM, about 0.46 mM, about 0.47 mM, about 0.48 mM, about 0.49 mM, about 0.5, about 0.55 mM, or about 0.6 mM,) magnesium chloride. Although the formulation solution contains no added calcium, the pharmaceutical composition made up from the AAV preparation and the formulation solution may have a trace amount of calcium that is carried over for the AAV manufacturing and purification process. For example, the pharmaceutical composition may contain no more than about 0.10 mM (e.g., no more than about 0.09, 0.07, 0.05, 0.03, or 0.01 mM) calcium when measured by a colorimetric assay. In some embodiments, the pharmaceutical composition contains no detectable calcium as measured by a colorimetric assay. In some embodiments, the pharmaceutical composition contains no calcium (i.e., 0 mM calcium).

[0047] The formulation solution may contain a polyol such as mannitol, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, lactitol, ethylene glycol, propylene glycol, polyethylene glycol, inositol, fructose, glucose, mannose, sucrose, sorbose, xylose, lactose, maltose, dextran, pullulan, dextrin, cyclodextrins, soluble starch, hydroxyethyl starch, water-soluble glucans, or mixtures thereof. In some embodiments, the formulation solution contains about 0.5% to 2% (e.g., about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1%) (w/v) sucrose.

[0048] The formulation solution may contain a nonionic or ionic hydrophilic surfactant. Example of surfactants are a polysorbate, poloxamer, triton, sodium dodecyl sulfate, sodium laurel sulfate, sodium octyl glycoside, lauryl-sulfobetaine, myristyl-sulfobetaine, linoleyl-sulfobetaine, stearyl-sulfobetaine, lauryl-sarcosine, myristyl-sarcosine, linoleyl-sarcosine,

stearyl-sarcosine, linoleyl-betaine, myristyl-betaine, cetyl-betaine, lauroamidopropyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine, myristamidopropyl-betaine, palmidopropyl-betaine, isostearamidopropyl-betaine, myristamidopropyl-dimethylamine, palmidopropyl-dimethylamine, isostearamidopropyl-dimethylamine, sodium methyl cocoyl-taurate, disodium methyl oleyl- taurate, dihydroxypropyl PEG-5 linoleammonium chloride, polyethylene glycol, polypropylene glycol, sorbitan monoesters (e.g., Spans), acid esters of glycerol, and mixtures thereof. In some embodiments, the surfactant can be polysorbate (PS) 20, PS-21, PS-40, PS-60, PS-61, PS-65, PS-80, PS-81, PS-85, PEG-3350, poloxamer 188, and mixtures thereof. In some embodiments, the formulation solution contains about 0.01% to 0.1% (e.g., about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 0.1%) (w/v) poloxamer 188.

[0049] In particular embodiments, the pharmaceutical composition comprises an AAV vector in Formulation F2 or F3. The ingredients for F2 and F3 are shown in **Table A** below.

Dulbecco's phosphate buffered saline (DPBS) with calcium and magnesium is a commonly used formulation for cell culture applications. F0 is another prior, calcium-containing formulation.

As shown in the Examples below, F2 and F3 are superior to DPBS and F0 in formulating AAV.

Table A. Formulation Comparison

Component (unit)	DPBS	F0	F2	F3
NaCl (mM)	136.89	171.80	171.80	171.80
KCl (mM)	2.68	2.68	2.68	2.68
Na ₂ HPO ₄ (mM)	8.10	8.10	8.10	8.10
KH ₂ PO ₄ (mM)	1.47	1.47	1.47	1.47
CaCl ₂ (mM)	0.90	0.90	0.0	0.0
MgCl ₂ (mM)	0.50	0.50	0.49	1.40
Sucrose (% w/v)	0.0	1.00%	1.00%	1.00%
Poloxamer 188 (% w/v)	0.0	0.05%	0.05%	0.05%

[0050] As used herein, the concentrations of the various ingredients in the formulations may be expressed with zero, one, or two decimal places. Thus, for example, in F2, the concentrations of NaCl, KCl, Na₂HPO₄, KH₂PO₄, MgCl₂, and sucrose may be expressed respectively as 171.80 (or 171.8 or 172) mM, 2.68 (or 2.7) mM, 8.10 (or 8.1 or 8) mM, 1.47 (or 1.5) mM, 0.49 (or 0.5) mM, and 1.00% (or 1.0% or 1%) (w/v). In F3, the concentrations of NaCl, KCl, Na₂HPO₄,

KH₂PO₄, MgCl₂, and sucrose may be expressed respectively as 171.80 (or 171.8 or 172) mM, 2.68 (or 2.7) mM, 8.10 (or 8.1 or 8) mM, 1.47 (or 1.5) mM, 1.40 (or 1.4) mM, and 1.00% (or 1.0% or 1%) (w/v).

[0051] The pharmaceutical compositions may further comprise one or more preservatives such as ascorbic acid (vitamin C), sulfites, sorbates, benzoates, phenol, m-cresol, benzyl alcohol, benzalkonium chloride, phenoxyethanol, and/or parabens (e.g., methyl paraben). In some embodiments, the pharmaceutical compositions do not contain any added preservatives.

[0052] The pharmaceutical compositions may comprise also other reagents that enhance the effectiveness of the pharmaceutical composition. The pharmaceutical composition may contain delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, and vesicles.

III. Exemplary Recombinant AAV

[0053] In exemplary embodiments, the present disclosure provides improved pharmaceutical compositions comprising rAAV vector for factor VIII gene therapy. The rAAV vector, termed PF-07055480/SB-525 (or “SB-525” herein), is of the 2/6 pseudo serotype, which comprises an AAV6 capsid and a recombinant genome having AAV2 inverted terminal repeats (ITR). SB-525’s genome carries an expression cassette encoding a B-domain-deleted (BDD) version of human factor VIII (FVIII). *See, e.g.,* WO 2017/074526 (sequence #37). SB-525 is administered as an intravenous (IV) dose and possesses liver-specific tropism to provide long-term hepatic production of factor VIII protein in patients with hemophilia A. *See* WO 2020/028830. The secreted FVIII protein has the same amino acid sequence as approved recombinant anti-hemophilic factors (Refacto® and Xyntha®)

[0054] SB-525’s genome comprises an expression cassette for a human factor VIII BDD version, which has the amino acid sequence shown below:

```

MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPP
NTSVVYKKTLFVEFTDHLFNIAPRPPWMGLLGPTIQAEVYD TVVITLKNMASHPVSLH
AVGVSYWKASEGA EYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSY
LSHVDLVKDLNSGLIGALLVCREGLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLM
QDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTP EVHSIFLEGHTF
LVRNHRQASLEISPIITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQL
RMKNNEEAEDYDDDLTDSEMDVVRFD DDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWD
YAPLV LAPDDRSYKSQYLNNGPQRI GRKYKKVRFMAYTDETFKTREAIQHESGILGPLL
YGEVGD TLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYK

```

WTVTVEDGPTKSDPRCLTRYYSFVNMERDLASGLIGPLLCYKESVDQQRGNQIMSDKR
 NVILFSVFDENRSWYLTENIQRFLEPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVC
 LHEVAYWYILSIGAQTDFLSVFFSGYTFKHKVMYEDTLTLFPFSGETVFMSPENPGLWI
 LGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFQKTRHYFIA
 LKRHQREITRRTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKTRHYFIA
 AVERLWDYGMSSSPHVLNRNRAQSGSVPQFKKVVFQEFDTGDSFTQPLYRGELNEHLGLLG
 PYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQQRQGAEPKRFVKNPNETKTYFWKV
 QHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGGLIGPLLVCHTNTLNPAHGRQVTVQEFAL
 FFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQD
 QRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPKAGIW
 RVECLIGEHLHAGMSTLFLVYSNKCQTPGLMASGHIRDFQITASGQYGQWAPKLARLHY
 SGSINAWSTKEPFSWIKVDLLAPMI IHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQT
 YRGNSTGTLMVFFGNVDSSGIKHNI FNPPIIARYIRLHPHTHYSIRSTLRMELMGCDLNS
 CSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQV
 DFQKTMKVTGVTQTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVVFQGNQDSFT
 PVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY (SEQ ID NO:1)

[0055] The signal peptide portion of SEQ ID NO:1 is shown in box above and is cleaved off when the protein is secreted.

[0056] The SB-525 genome comprises the following nucleotide sequence:

1	CTGCGCGCTC	GCTCGCTCAC	TGAGGCCGCC	CGGGCAAAGC	CCGGGCGTCG	GGCGACCTTT
61	GGTCGCCCCG	CCTCAGTGAG	CGAGCGAGCG	CGCAGAGAGG	GAGTGGCCAA	CTCCATCACT
121	AGGGGTTCTT	GCGGCCTAAG	CTTGGAACCA	TTGCCACCTT	CAGGGGGAGG	CTGCTGGTGA
181	ATATTAACCA	AGATCACCCC	AGTTACCGGA	GGAGCAAACA	GGGACTAAGT	TCACACGCGT
241	GGTACCGTCT	GTCTGCACAT	TTCGTAGAGC	GAGTGTTCG	ATACTCTAAT	CTCCCTAGGC
301	AAGGTTTCATA	TTTGTGTAGG	TTACTTATTC	TCCTTTTGT	GACTAAGTCA	ATAATCAGAA
361	TCAGCAGGTT	TGGAGTCAGC	TTGGCAGGGA	TCAGCAGCCT	GGGTTGGAAG	GAGGGGGTAT
421	AAAAGCCCCCT	TCACCAGGAG	AAGCCGTCAC	ACAGATCCAC	AAGCTCCTGA	AGAGGTAAGG
481	GTTTAAGTTA	TCGTTAGTTC	GTGCACCATT	AATGTTTAAT	TACCTGGAGC	ACCTGCCTGA
541	AATCATTTTTT	TTTTTCAGGTT	GGCTAGTATG	CAGATCGAGC	TCTCCACCTG	CTTCTTTCTG
601	TGCCTGTTGA	GATTCTGCTT	CAGCGCCACC	AGGAGATACT	ACCTGGGGGC	TGTGGAGCTG
661	AGCTGGGACT	ACATGCAGTC	TGACCTGGGG	GAGCTGCCTG	TGGATGCCAG	GTTCCCCCCC
721	AGAGTGCCCA	AGAGCTTCCC	CTTCAACACC	TCTGTGGTGT	ACAAGAAGAC	CCTGTTTGTG
781	GAGTTCACTG	ACCACCTGTT	CAACATTGCC	AAGCCCAGGC	CCCCCTGGAT	GGGCCTGCTG
841	GGCCCCACCA	TCCAGGCTGA	GGTGTATGAC	ACTGTGGTGA	TCACCCTGAA	GAACATGGCC
901	AGCCACCCTG	TGAGCCTGCA	TGCTGTGGGG	GTGAGCTACT	GGAAGGCCTC	TGAGGGGGCT
961	GAGTATGATG	ACCAGACCAG	CCAGAGGGAG	AAGGAGGATG	ACAAGGTGTT	CCCTGGGGGC
1021	AGCCACACCT	ATGTGTGGCA	GGTGTGGAAG	GAGAATGGCC	CCATGGCCTC	TGACCCCCTG
1081	TGCCTGACCT	ACAGCTACCT	GAGCCATGTG	GACCTGGTGA	AGGACCTGAA	CTCTGGCCTG
1141	ATTGGGGCCC	TGCTGGTGTG	CAGGGAGGGC	AGCCTGGCCA	AGGAGAAGAC	CCAGACCCTG
1201	CACAAGTTCA	TCCTGCTGTT	TGCTGTGTTT	GATGAGGGCA	AGAGCTGGCA	CTCTGAAACC
1261	AAGAACAGCC	TGATGCAGGA	CAGGGATGCT	GCCTCTGCCA	GGGCCTGGCC	CAAGATGCAC
1321	ACTGTGAATG	GCTATGTGAA	CAGGAGCCTG	CCTGGCCTGA	TTGGCTGCCA	CAGGAAGTCT
1381	GTGTACTGGC	ATGTGATTGG	CATGGGCACC	ACCCCTGAGG	TGCACAGCAT	CTTCCTGGAG
1441	GGCCACACCT	TCCTGGTCAG	GAACCACAGG	CAGGCCAGCC	TGGAGATCAG	CCCCATCACC
1501	TTCCTGACTG	CCCAGACCCT	GCTGATGGAC	CTGGGCCAGT	TCCTGCTGTT	CTGCCACATC
1561	AGCAGCCACC	AGCATGATGG	CATGGAGGCC	TATGTGAAGG	TGGACAGCTG	CCCTGAGGAG
1621	CCCCAGCTGA	GGATGAAGAA	CAATGAGGAG	GCTGAGGACT	ATGATGATGA	CCTGACTGAC
1681	TCTGAGATGG	ATGTGGTGAG	GTTTGATGAT	GACAACAGCC	CCAGCTTCAT	CCAGATCAGG

1741	TCTGTGGCCA	AGAAGCACCC	CAAGACCTGG	GTGCACTACA	TTGCTGCTGA	GGAGGAGGAC
1801	TGGGACTATG	CCCCCCTGGT	GCTGGCCCCCT	GATGACAGGA	GCTACAAGAG	CCAGTACCTG
1861	AACAATGGCC	CCCAGAGGAT	TGGCAGGAAG	TACAAGAAGG	TCAGGTTCAT	GGCCTACACT
1921	GATGAAACCT	TCAAGACCAG	GGAGGCCATC	CAGCATGAGT	CTGGCATCCT	GGGCCCCCTG
1981	CTGTATGGGG	AGGTGGGGGA	CACCCTGCTG	ATCATCTTCA	AGAACCAGGC	CAGCAGGCCC
2041	TACAACATCT	ACCCCCATGG	CATCACTGAT	GTGAGGCCCC	TGTACAGCAG	GAGGCTGCCC
2101	AAGGGGGTGA	AGCACCTGAA	GGA CTTCCCC	ATCCTGCCTG	GGGAGATCTT	CAAGTACAAG
2161	TGGACTGTGA	CTGTGGAGGA	TGGCCCCACC	AAGTCTGACC	CCAGGTGCCT	GACCAGATAC
2221	TACAGCAGCT	TTGTGAACAT	GGAGAGGGAC	CTGGCCTCTG	GCCTGATTGG	CCCCCTGCTG
2281	ATCTGCTACA	AGGAGTCTGT	GGACCAGAGG	GGCAACCAGA	TCATGTCTGA	CAAGAGGAAT
2341	GTGATCCTGT	TCTCTGTGTT	TGATGAGAAC	AGGAGCTGGT	ACCTGACTGA	GAACATCCAG
2401	AGGTTCCCTGC	CCAACCCTGC	TGGGGTGCAG	CTGGAGGACC	CTGAGTTCCA	GGCCAGCAAC
2461	ATCATGCACA	GCATCAATGG	CTATGTGTTT	GACAGCCTGC	AGCTGTCTGT	GTGCCTGCAT
2521	GAGGTGGCCT	ACTGGTACAT	CCTGAGCATT	GGGGCCCAGA	CTGACTTCCT	GTCTGTGTTT
2581	TTCTCTGGCT	ACACCTTCAA	GCACAAGATG	GTGTATGAGG	ACACCCTGAC	CCTGTTCCCC
2641	TTCTCTGGGG	AGACTGTGTT	CATGAGCATG	GAGAACCCTG	GCCTGTGGAT	TCTGGGCTGC
2701	CACAACTCTG	ACTTCAGGAA	CAGGGGCATG	ACTGCCCTGC	TGAAAGTCTC	CAGCTGTGAC
2761	AAGAACACTG	GGGACTACTA	TGAGGACAGC	TATGAGGACA	TCTCTGCCTA	CCTGCTGAGC
2821	AAGAACAATG	CCATTGAGCC	CAGGAGCTTC	AGCCAGAATC	CACCCGTCCT	TAAGCGCCAT
2881	CAGCGCGAGA	TCACCAGGAC	CACCCTGCAG	TCTGACCAGG	AGGAGATTGA	CTATGATGAC
2941	ACCATCTCTG	TGGAGATGAA	GAAGGAGGAC	TTTGACATCT	ACGACGAGGA	CGAGAACCAG
3001	AGCCCCAGGA	GCTTCCAGAA	GAAGACCAGG	CACTACTTCA	TTGCTGCTGT	GGAGAGGCTG
3061	TGGGACTATG	GCATGAGCAG	CAGCCCCCAT	GTGCTGAGGA	ACAGGGCCCA	GTCTGGCTCT
3121	GTGCCCCAGT	TCAAGAAGGT	GGTGTTCAG	GAGTTCACTG	ATGGCAGCTT	CACCCAGCCC
3181	CTGTACAGAG	GGGAGCTGAA	TGAGCACCTG	GGCCTGCTGG	GCCCCTACAT	CAGGGCTGAG
3241	GTGGAGGACA	ACATCATGGT	GACCTTCAGG	AACCAGGCCA	GCAGGCCCTA	CAGCTTCTAC
3301	AGCAGCCTGA	TCAGCTATGA	GGAGGACCAG	AGGCAGGGGG	CTGAGCCCAG	GAAGAACTTT
3361	GTGAAGCCCA	ATGAAACCAA	GACCTACTTC	TGGAAGGTGC	AGCACCACAT	GGCCCCCACC
3421	AAGGATGAGT	TTGACTGCAA	GGCCTGGGCC	TACTTCTCTG	ATGTGGACCT	GGAGAAGGAT
3481	GTGCACTCTG	GCCTGATTGG	CCCCCTGCTG	GTGTGCCACA	CCAACACCCT	GAACCCTGCC
3541	CATGGCAGGC	AGGTGACTGT	GCAGGAGTTT	GCCCTGTTCT	TCACCATCTT	TGATGAAACC
3601	AAGAGCTGGT	ACTTCACTGA	GAACATGGAG	AGGAACTGCA	GGGCCCCCTG	CAACATCCAG
3661	ATGGAGGACC	CCACCTTCAA	GGAGAACTAC	AGGTTCATG	CCATCAATGG	CTACATCATG
3721	GACACCCTGC	CTGGCCTGGT	GATGGCCCAG	GACCAGAGGA	TCAGGTGGTA	CCTGCTGAGC
3781	ATGGGCAGCA	ATGAGAACAT	CCACAGCATC	CACTTCTCTG	GCCATGTGTT	CACTGTGAGG
3841	AAGAAGGAGG	AGTACAAGAT	GGCCCTGTAC	AACCTGTACC	CTGGGGTGTT	TGAGACTGTG
3901	GAGATGCTGC	CCAGCAAGGC	TGGCATCTGG	AGGGTGGAGT	GCCTGATTGG	GGAGCACCTG
3961	CATGCTGGCA	TGAGCACCCCT	GTTCCCTGGT	TACAGCAACA	AGTGCCAGAC	CCCCCTGGGC
4021	ATGGCCTCTG	GCCACATCAG	GGACTTCCAG	ATCACTGCCT	CTGGCCAGTA	TGGCCAGTGG
4081	GCCCCCAAGC	TGGCCAGGCT	GCACTACTCT	GGCAGCATCA	ATGCCTGGAG	CACCAAGGAG
4141	CCCTTCAGCT	GGATCAAGGT	GGACCTGCTG	GCCCCCATGA	TCATCCATGG	CATCAAGACC
4201	CAGGGGGCCA	GGCAGAAAGT	CAGCAGCCTG	TACATCAGCC	AGTTCATCAT	CATGTACAGC
4261	CTGGATGGCA	AGAAGTGGCA	GACCTACAGG	GGCAACAGCA	CTGGCACCCCT	GATGGTGTTC
4321	TTTGGCAATG	TGGACAGCTC	TGGCATCAAG	CACAACATCT	TCAACCCCCC	CATCATTGCC
4381	AGATACATCA	GGCTGCACCC	CACCCACTAC	AGCATCAGGA	GCACCCTGAG	GATGGAGCTG
4441	ATGGGCTGTG	ACCTGAACAG	CTGCAGCATG	CCCCTGGGCA	TGGAGAGCAA	GGCCATCTCT
4501	GATGCCCAGA	TCACTGCCAG	CAGCTACTTC	ACCAACATGT	TTGCCACCTG	GAGCCCCAGC
4561	AAGGCCAGGC	TGCATCTGCA	GGGCAGGAGC	AATGCCTGGA	GGCCCCAGGT	CAACAACCCC
4621	AAGGAGTGGC	TGCAGGTGGA	CTTCCAGAAG	ACCATGAAGG	TGACTGGGGT	GACCACCCAG
4681	GGGGTGAAGA	GCCTGCTGAC	CAGCATGTAT	GTGAAGGAGT	TCCTGATCAG	CAGCAGCCAG
4741	GATGGCCACC	AGTGGACCCT	GTTCTTCCAG	AATGGCAAGG	TGAAGGTGTT	CCAGGGCAAC
4801	CAGGACAGCT	TCACCCCTGT	GGTGAACAGC	CTGGACCCCC	CCCTGCTGAC	CAGATACCTG
4861	AGGATTACAC	CCCAGAGCTG	GGTGCACCAG	ATTGCCCTGA	GGATGGAGGT	GCTGGGCTGT
4921	GAGGCCCAGG	ACCTGTACTG	AGGATCCAAT	AAAATATCTT	TATTTTCATT	ACATCTGTGT
4981	GTTGGTTTTT	TGTGTGTTTT	CCTGTAACGA	TCGGGCTCGA	GCGCAGGAAC	CCCTAGTGAT
5041	GGAGTTGGCC	ACTCCCTCTC	TGCGCGCTCG	CTCGCTCACT	GAGGCCGCCC	GGGCTTTGCC

5101 CGGGCGGCCT CAGTGAGCGA GCGAGCGCGC AG (SEQ ID NO:2)

[0057] In the above sequence, the left (5') ITR (AAV2 ITR) spans nucleotides 1-130, and the right (3') ITR (AAV2 ITR) spans nucleotides 5025-5132. Both ITRs are boxed.

IV. Use of Recombinant AAV Formulations

[0058] The pharmaceutical compositions of the invention may be supplied in an article of manufacture (e.g., a kit) comprising vials (e.g., pre-treated glass vials or COP vials) and instructions for use. In some embodiments, each vial contains about $1\text{E}+11$ to $1\text{E}+15$ vg per mL of AAV in 0.5-50 mL (e.g., 1-10 mL). In particular embodiments, each vial contains $5\text{E}+12$ to $1\text{E}+14/\text{mL}$ (e.g., $1\text{E}+13$ vg/mL). In certain embodiments, each vial contains $6\text{E}+13$ vg in 6 mL.

[0059] The compositions may be administered to the patients once or more than once. For example, the compositions may be administered to the patients with an interval of no less than 1 month, 3 months, 6 months, 9 months, or one year. In some embodiments, the composition may be administered to the patients with an interval of no less than two, five, seven, ten, or fifteen years. The pharmaceutical composition may be provided to a patient in need thereof through a route appropriate for the disease to be treated. For example, the compositions may be administered through intravenous injection, intraarterially injection, intracranial injection, intraperitoneal injection, portal vein injection, or intramuscular injection. For example, the SB-525 pharmaceutical compositions may be provided intravenously to hemophilia A patients at $1\text{E}+11$ to $1\text{E}+15$ vg/kg, such as $1\text{E}+11$ to $1\text{E}+14$ (e.g., $1\text{E}+12$ to $1\text{E}+14$) vg/kg. In some embodiments, the SB-525 pharmaceutical compositions may be provided intravenously to hemophilia A patients at $5\text{E}+11$, $6\text{E}+11$, $7\text{E}+11$, $8\text{E}+11$, $9\text{E}+11$, $1\text{E}+12$, $2\text{E}+12$, $3\text{E}+12$, $4\text{E}+12$, $5\text{E}+12$, $6\text{E}+12$, $7\text{E}+12$, $8\text{E}+12$, $9\text{E}+12$, $1\text{E}+13$, $2\text{E}+13$, $3\text{E}+13$, $4\text{E}+13$, $5\text{E}+13$, $6\text{E}+13$, $7\text{E}+13$, $8\text{E}+13$, $9\text{E}+13$, or $1\text{E}+14$ vg/kg. In some embodiments, the SB-525 compositions are provided intravenously to hemophilia A patients at a dose of about $6\text{E}+13$ vg/kg.

[0060] In some embodiments, the patients have with severe or moderate hemophilia A. In further some embodiments, the patients have no inhibitors (alloantibodies to Factor VIII). In certain embodiments, the patients do not have neutralizing antibodies to AAV6. The patients may be adult or adolescent patients (≥ 12 years of age) or pediatric patients (< 12 years of age).

[0061] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. In case of conflict, the present specification, including definitions, will control. Generally, nomenclature used in connection with, and techniques of, cardiology, medicine, medicinal and pharmaceutical chemistry, and cell biology described herein are those well-known and commonly used in the art. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Throughout this specification and embodiments, the words "have" and "comprise," or variations such as "has," "having," "comprises," or "comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. All publications and other references mentioned herein are incorporated by reference in their entirety. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art. As used herein, the term "approximately" or "about" as applied to one or more values of interest refers to a value that is similar to a stated reference value. In certain embodiments, the term refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context.

[0062] In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLES

[0063] The following Examples describe a study in which the inventors discovered a current SB-525 formulation formed precipitates upon freeze/thaw cycling, a common test for assessing the shelf-life and long-term stability of biological products. The inventors discovered that precipitates also formed in the buffer formulation alone (i.e., buffer formulation containing no

active viral vector ingredient). The inventors thus set out to find a new formulation that would circumvent this problem.

[0064] In the study, the SB-525 viral preparations were prepared and formulated at approximately $1.0\text{E}+13$ vg/mL in phosphate-buffered saline (PBS) with the addition of CaCl_2 , MgCl_2 , 35 mM NaCl, 1% sucrose, and 0.05% Kolliphor® P 188 (poloxamer 188), filled at 5 mL into 6 mL Aseptic Technologies crystal closed vials, and stored at $\leq -65^\circ\text{C}$. For the stability tests, SB-525 compositions were placed on stability at -0°C , 5°C , and 25°C for up to 24 months (**Table 5**). Five cycles of uncontrolled freeze/thaw (F/T) (**Table 1**) and a 24-hour agitation (AG) (**Table 2**) were also performed. Drug product (DP) quality attributes were analyzed according to **Table 5** to **Table 8**.

Example 1: Freeze/Thaw Cycling and Agitation Tests

Materials and Methods

[0065] The SB-525 was provided at $1.0\text{E}+13$ vg/mL nominal in a formulation buffer containing the following ingredients: 0.90 mM CaCl_2 , 0.49 mM MgCl_2 , 2.68 mM KCl, 1.47 mM KH_2PO_4 , 172 mM NaCl, 8.10 mM Na_2HPO_4 , 1% (w/v) sucrose, 0.05% (w/v) poloxamer 188, pH 7.36. 23 vials were stored at -70°C , 11 at 5°C , and 8 at 25°C .

[0066] For freeze/thaw (F/T) cycling tests, samples were uncontrolled F/T cycled for three and five cycles as shown in **Table 1**.

Table 1. DP Uncontrolled F/T Cycling

F/T Cycling	Day 1	Day 2		Day 3		Day 4		Day 5	
	4 pm	8 am	4 pm	8 am	4 pm	8 am	4 pm	8 am	4 pm
3	-80°C	25°C	-80°C	25°C	-80°C	25°C			
5	-80°C	25°C	-80°C	25°C	-80°C	25°C	-80°C	25°C	-80°C

[0067] For agitation tests, samples were agitated at room temperature as shown in **Table 2**.

Table 2. DP Agitation Setup

Agitation Stability	T_0	$T_{24\text{Hr}}$
	Day 1 (8 am)	Day 2 (8 am)
300 rpm	Use Stability T_0	Pull 24Hr material

[0068] The vials stored at -70°C, 5°C, at 25°C, respectively, were analyzed for (i) appearance (liquid), pH, dynamic light scattering (DLS), and high accuracy liquid particle counter (HIAC); (ii) vg identity (qPCR), vg titer (qPCR), capsid titer (ELISA), capsid identity (ELISA), and infectious titer (TCID₅₀); (iii) *in vitro* FVIII Activity (bioassay); or (iv) UV 260/280, reduced CE-SDS, SEC titer_{260/280}.

[0069] Samples that went through F/T cycling were analyzed for (i) appearance (liquid), pH, osmolarity, DLS, HIAC; (ii) vg titer (qPCR), capsid titer and identity (ELISA), reduced SDS-PAGE, and infectious titer (TCID₅₀); or (iii) UV 260/280, SEC titer_{260/280}, RP-HPLC, *in vitro* FVIII Activity (bioassay), and reduced CE-SDS.

[0070] Samples that went through 24-hour agitation (AG) were analyzed for (i) appearance (liquid), pH, osmolarity, DLS, and HIAC; (ii) vg titer (qPCR), capsid titer and identity (ELISA), reduced SDS-PAGE, infectious titer (TCID₅₀); or (iii) UV 260/280, SEC titer_{260/280}, RP-HPLC, *in vitro* FVIII activity (bioassay), and reduced CE-SDS.

Results

[0071] Results from the SB-525 DP stability, 5 cycles of uncontrolled F/T, and 24-hour agitation arms are described below.

[0072] As shown in **Table 3** below, there was no significant change in color, clarity, pH, hydrodynamic radius as measured by DLS, vg titer, capsid titer, capsid purity as measured by SDS-PAGE, infectious titer, UV 260/280 (a surrogate measure for empty:full capsid ratio), and biological activity (% relative potency) when the samples were stored at the tested conditions for up to one month. There was a change in visible particles at 5°C and 25°C. All the samples were frozen and appeared white and opaque at T zero (T₀).

Table 3. Stability Results

Test		Storage	T ₀ *	T _{1M} ²
Appearance, Liquid	Color	-70°C	Colorless, clear, no precipitates, no contaminants	B6
		5°C		B6
		25°C		B6
	Clarity	-70°C		<= Ref. I
		5°C		<= Ref. I
		25°C		<= Ref. I
	Visible Particles	-70°C		EFVP
		5°C		1-5 particles
		25°C		TMTC
pH		-70°C	7.3	7.3

Test		Storage	T ₀ *	T _{1M} ²
		5°C		7.3
		25°C		7.1
DLS	Z-average – Diffusion Coefficient (cm ² /s)	-70°C	-	1.70e ⁻⁷
		5°C		1.70e ⁻⁷
		25°C		1.70e ⁻⁷
	Z-average – Radius (nm)	-70°C	22.3 (diameter)	14.7
		5°C		14.8
		25°C		14.4
	Peak 1 – Diffusion Coefficient (cm ² /s)	-70°C	-	1.74e ⁻⁷
		5°C		1.69e ⁻⁷
		25°C		1.70e ⁻⁷
	Peak 1 – radius (nm)	-70°C		14.2
		5°C		14.6
		25°C		14.5
	Peak 2 – Diffusion Coefficient (cm ² /s)	-70°C		9.42e ⁻¹⁰
		5°C		1.26e ⁻⁹
		25°C		-
	Peak 2 – radius (nm)	-70°C		2658.7
		5°C		2261.8
		25°C		-
Vg titer by qPCR (vg/mL) ¹		-70°C	8.74E+12	9.77E+12
		5°C		1.01E+13
		25°C		9.98E+12
Capsid ELISA (capsids/mL)		-70°C	2.76E+13	2.52E+13
		5°C		2.53E+13
		25°C		2.66E+13
SDS-PAGE		-70°C	VP1, VP2, and VP3 comparable to reference. No other bands ≥ sensitivity control observed (% Purity VP1, VP2, VP3 combined) = 100%	VP1, VP2, and VP3 comparable to reference. No other bands ≥ sensitivity control observed (% Purity VP1, VP2, VP3 combined) = 100%
		5°C		
		25°C		
Infectious Titer TCID ₅₀ (TCID ₅₀ /mL)		-70°C	1.12E+9	3.56E+9
		5°C		2.00E+9
		25°C		1.12E+9
SEC UV 260/280 Ratio		-70°C	1.37	1.36
		5°C		1.36
		25°C		1.36
<i>In vitro</i> FVIII Activity/ Functional Bioassay (% Relative Potency)		-70°C	85 ³	80
		5°C		80
		25°C		69

*T₀: all analytics, except functional bioassay, performed per release testing

¹ T₀ re-test of Vector Genome Identity & Titer by qPCR was performed

² Study terminated after T1M due to particle detection in DP; investigation was initiated

³ T₀ re-test for Bioassay (% Relative Potency) against a different reference material

EFVP: Essentially Free of Visible Particles

TMTC: Too many to Count

N.T.: Not tested

[0073] As shown in **Table 4**, there was no significant change in capsid purity after one month at all storage conditions.

Table 4. Capsid Purity Stability Results

Time Point	Storage	Capsid (%)	VP1 (%)	VP2 (%)	VP3 (%)	Other (%)
T ₀		94.3	2.2	3.4	94.4	5.7
T _{1M}	-70°C	95.1	1.1	3.1	95.8	4.9
	5°C	95.0	2.1	3.2	94.7	5.0
	25°C	94.8	1.9	3.0	95.1	5.2

[0074] As shown in **Table 5**, there was no significant aggregation or formation of high molecular weight species (HMWS) after one month at all storage conditions (NMT: not more than; LOQ: limit of quantification).

Table 5. SEC Titer Stability Results After One Month Under Intended, Accelerated, and Stressed Storage Conditions

Time Point	Storage	Viral Particle (vp) Titer (vp/mL)	Monomer (%)	HMWS (%)	LOQ
T ₀		5.12E+13	100	NMT 1.0	1.01E+12
T _{1M}	-70°C	2.65E+13	100	NMT 1.0	1.01E+12
	5°C	2.57E+13	100	NMT 1.0	1.01E+12
	25°C	3.31E+13	100	NMT 1.0	1.01E+12

[0075] As shown in **Table 6**, there was no significant increase in subvisible particles (per HIAC) after one month at all storage conditions. All time points showed particles below the USP <787> standard in regard to the $\geq 10 \mu\text{m}$ and the $\geq 25 \mu\text{m}$ ranges, where acceptance criteria are no more than 6,000 particles $> 10 \mu\text{m}$ per container and no more than 600 particles $> 25 \mu\text{m}$ per container.

Table 6. HIAC Stability Results

Storage	T ₀ (particles/container)		T _{1M} (particles/mL)				
	$\geq 10 \mu\text{m}$	$\geq 25 \mu\text{m}$	$\geq 2 \mu\text{m}$	$\geq 5 \mu\text{m}$	$\geq 8 \mu\text{m}$	$\geq 10 \mu\text{m}$	$\geq 25 \mu\text{m}$
-70°C	10	3	143	11	1	0	0
5°C			626	96	24	15	0
25°C			478	94	15	4	1

[0076] As shown in **Table 7**, there was no significant change in color, clarity, pH, hydrodynamic radius as measured by DLS, vg titer, capsid titer, infectious titer, UV 260/280 (surrogate for empty:full capsid ratio), capsid purity as measured by RP-HPLC, and biological activity (% relative potency) upon F/T/AG stress. There was a change in visible particles for F/T.

Table 7. Cycle Uncontrolled F/T & 24-Hour AG Results

Test		Treatment	Results
Appearance	Color	F/T	B9 ¹
		AG	B9
	Clarity	F/T	<= REF 1 ²
		AG	<= REF 1
	Visible Particles	F/T	TMTC
		AG	Essentially free of visible particles (EFVP)
pH		F/T	7.2
		AG	7.3
Osmolality (mOsm/kg)		F/T	387
		AG	388
DLS	Z-average – Diffusion Coefficient (cm ² /s)	F/T	1.70e ⁻⁷
		AG	1.67e ⁻⁷
	Z-average –Radius (nm)	F/T	14.5
		AG	14.7
	Peak 1 – Diffusion Coefficient (cm ² /s)	F/T	1.69e ⁻⁷
		AG	1.56e ⁻⁷
	Peak 1 – radius (nm)	F/T	14.5
		AG	15.7
Vg titer by qPCR (vg/mL)		F/T	8.44E+12
		AG	8.63E+12
Capsid ELISA (capsids/mL)		F/T	2.08E+13
		AG	2.00E+13
SDS-PAGE		F/T	VP1, VP2, and VP3 comparable to reference. No other bands ≥ sensitivity control observed (% Purity VP1, VP2, VP3 combined) = 100%
		AG	
Infectious Titer TCID50 (TCID ₅₀ /mL)		F/T	9.29E+8
		AG	2.42E+9
UV 260/280 Ratio		F/T	1.32
		AG	1.32
SEC UV 260/260 Ratio		F/T	1.35
		AG	1.35
RP-HPLC	Capsid (%)	F/T	98.9

Test		Treatment	Results
		AG	99.0
	Other (%)	F/T	1.1
		AG	1.0
<i>in vitro</i> FVIII Activity/ Functional Bioassay (% Relative Potency)		F/T	85
		AG	80

¹ Color is not more intense or more opalescent than reference standard listed.

² Clarity is not more opalescent than reference standard listed.

[0077] As shown in **Table 8**, there was no significant change in reduced CE-SDS upon F/T/AG stress.

Table 8. 5 Cycle Uncontrolled F/T & 24-Hour AG CE-SDS-Reduced Results

Treatment	Capsid (%)	VP1 (%)	VP2 (%)	VP3 (%)	Other (%)
F/T	95.1	2.0	3.0	95.0	4.9
AG	95.2	2.0	3.2	94.8	4.8

[0078] As shown in **Table 9**, there was no significant aggregation/HMWS formation upon F/T/AG stress.

Table 9. 5 Cycle Uncontrolled F/T & 24-Hour AG SEC Titer Results

Treatment	Viral Particle Titer (vp/mL)	Monomer (%)	HMWS (%)	LOQ
F/T	4.95E+13	100	0	1.01E+12
AG	5.05E+13	100	0	1.01E+12

[0079] As shown in **Table 10**, there was a significant increase in subvisible particles (per HIAC) upon F/T. Particles upon F/T were above USP <787> standard with regard to the ≥ 10 μm and the ≥ 25 μm ranges; whereas particles upon AG were below USP <787> standard with regard to the ≥ 10 μm and the ≥ 25 μm ranges.

Table 10. 5 Cycle Uncontrolled F/T & 24-Hour AG HIAC Results

Treatment	≥ 2 μm (particles/mL)	≥ 5 μm (particles/mL)	≥ 8 μm (particles/mL)	≥ 10 μm (particles/mL)	≥ 25 μm (particles/mL)
F/T	24551	14051	8725	6576	710
AG	439	41	12	4	0

[0080] The above results demonstrate that the SB-525 samples showed no significant change in color, clarity, pH, hydrodynamic radius (as measured by dynamic light scattering), vg titer, capsid titer, infectious titer, empty:full capsid ratio (as measured by UV 260/280), biological activity (% relative potency), capsid purity (as measured by SDS-PAGE, reduced CE-SDS and RP-HPLC), or viral particle titer when stored up to one month at -70°C, 5°C, or 25°C.

Additionally, there was no significant change in color, clarity, pH, hydrodynamic radius (as measured by dynamic light scattering), vg titer, capsid titer, infectious titer, empty:full capsid ratio (as measured by UV 260/280), biological activity (% relative potency), capsid purity (as measured by SDS-PAGE, reduced CE-SDS, RP-HPLC), or viral particle titer upon F/T or AG stress, either. However, there was a significant increase in subvisible particles (per HIAC) upon F/T and an increase in visible particles after one month of storage at 5°C and 25°C. The study was terminated at one month because of these results.

Example 2: Characterization of Particulate Matter in DP Vials after F/T

[0081] The samples from the above stability tests of SB-525 formulations, in which particulate matter was observed, were analyzed further for isolation and identification.

[0082] Drug product samples that had undergone 5 freeze-thaw cycles (“DP after 5 F/T”) and samples that had been stored at 25°C for one month (DP after 1M at 25°C) were analyzed.

Particulate matter was isolated onto 0.8 µm gold filters. It was then imaged on the filter under partial ring lighting using a Keyence VHX6000 digital microscope at 150x magnification. The filters were then transferred to the Fourier transform infrared (FTIR) microscope where spectra were obtained for the material. FTIR spectra were compared against the KnowItAll database for known spectra. A portion of the DP after 1M at 25°C sample was also scraped off the filter onto a glass slide and imaged under plane polarized light and crossed polars using a Nikon Eclipse ME600 polarized light microscope. A portion of the gold filter was cut and analyzed under the JEOL6000 SEM equipped with an EDS module. The sample was also analyzed by Raman microscopy analysis.

[0083] For all samples, digital imaging showed a white solid that appeared to be semi-crystalline. Under crossed polars, the “DP after 5 F/T” sample did not exhibit any birefringence, suggesting it was either an amorphous substance or isotropic. SEM/EDS analysis showed large portions of oxygen, phosphorous, and calcium. FTIR analysis identified the material as a salt,

but further identification was required. Raman microscopy was able to detect peaks characteristic of calcium phosphate, suggesting the white particulate matter in all samples was calcium phosphate. **FIGs. 1A-F** summarize the particle characterization studies.

Example 3: Reformulation of SB-525

[0084] This example describes experiments testing new SB-525 formulations that can circumvent the precipitation problem observed above. These experiments assessed the short-term stability of SB-525 DP when reformulated to (1) remove calcium, (2) remove calcium and magnesium, or (3) increase sucrose to 8.5%. These changes were expected to prevent generation of particles by (1) removing the source of particles, (2) removing both divalent cations due to solubility concerns of MgCl_2 , or (3) increasing stability of the formulation against freeze-thaw stress, respectively. Two pilot batches were buffer exchanged and filled at 2.5 mL into 6 mL AT vials to mimic worst-case conditions for surface area to volume (SA/V) fill. After fill/finish, vials were subjected to 5 uncontrolled freeze-thaw cycles ($\leq -65^\circ\text{C}$ to ambient), and then placed on stability at $\leq -65^\circ\text{C}$ (intended storage), $2-8^\circ\text{C}$ (stressed; liquid storage), 25°C (accelerated; liquid storage), and 40°C (aggressive/forced degradation condition; liquid storage). These conditions were selected with the expectation of highlighting differences between formulations.

[0085] SB-525 virus was purified from the clarified bulk harvest and formulated at approximately $1.0\text{E}+13$ vg/mL in phosphate buffered saline (PBS) containing CaCl_2 , MgCl_2 , 35 mM NaCl, 1% Sucrose, and 0.05% Kolliphor® P 188 (poloxamer 188), filled into vials, and stored at $\leq -65^\circ\text{C}$.

Materials and Methods

[0086] The SB-525 formulated bulk drug substance contained: SB-525 ($1.0\text{E}+13$ vg/ mL nominal) in 0.90 mM CaCl_2 , 0.49 mM MgCl_2 , 2.68 mM KCl, 1.47 mM KH_2PO_4 , 172 mM NaCl, 8.10 mM Na_2HPO_4 , 1% (w/v) sucrose, 0.05% (w/v) poloxamer 188, pH 7.0-7.6, sterile filtered and stored in 125 mL HDPE bottles at $\leq -65^\circ\text{C}$. Na_2HPO_4 (sodium phosphate, dibasic, anhydrous), KH_2PO_4 (potassium phosphate monobasic), CaCl_2 (calcium chloride dihydrate), and MgCl_2 (magnesium chloride hexahydrate) were sourced from JT Baker or Fischer. Poloxamer 188 was sourced from BASF. Storage vials were 6 mL Aseptic Technologies (AT) Closed Crystal Vials (Aseptic Technologies; cat# VIA-060000), which are vials with primary container closure, cyclo-olefin copolymer (COC) with in-place thermoplastic elastomer stopper and yellow

cap. Prior to DP fill, the formulated bulk drug substance (FBDS) was filled into 125 mL high density polyethylene (HDPE) bottles and frozen to $\leq -65^{\circ}\text{C}$. Bottles were then thawed at ambient temperature, buffer exchanged, filtered, and DP filled into 6 mL AT vials using the Aseptic Technologies M1 unit. One pilot batch material was buffer exchanged via TFF using 50 kDa filter units at a pressure of approximately 40 psi for a total of 10 exchange volumes. The second pilot batch was buffer exchanged using Amicon stir cells over a 50 kDa NMW PES filter at approximately 40 psi for a total of 10 exchange volumes. The two exchange methods have been previously used for AAV without significant loss or adsorption of material.

[0087] The AT vials were filled 2.5 mL at a target of approximately $1.0\text{E}+13$ vg/mL, freeze thaw cycled 5 times at an uncontrolled rate from $\leq -65^{\circ}\text{C}$ to ambient conditions, and placed on stability in non-GMP storage units. Vials were subjected to the stability pull schedule outlined in **Table 11**, and tested by the methods listed in **Table 12**. Formulations tested are outlined in **Table 13**.

Table 11. Capsid Purity Stability Schedule

Storage Temp ($^{\circ}\text{C}$)	T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}	T _{5W}
-70 (± 10)	XABCD	-	-	-	-	XABC	XA
5 (± 3)		X	X	XA	X		XA
25 (± 3)		X	X	XAB	X		-
40 (± 3)		XABCF	XA	X	XF	-	-

Table 12. Analytical Testing

Test Code	Test Method
X	Appearance (Liquid)
A	pH
A	SEC – Aggregates, UV 260/280, Viral Particle Titer
B	Functional FVIII Bioassay
C	Light Obscuration with HIAC
D	Osmolality (freezing point depression)
D	P188
D	Sucrose
D	Reduced capillary gel electrophoresis (rCGE) (ratio and purity)
F	Mass Spec (deamidation)
B	Vector Genome Titer (qPCR)

Table 13. Formulations

Exchange Process	Material	Formulation	Difference from Control
	M05	Control	N/A

Exchange Process	Material	Formulation	Difference from Control
Millipore Amicon Stir Cell	M06	Ca Negative	Removed CaCl ₂
	M07	Ca /Mg Negative	Removed CaCl ₂ and MgCl ₂
	M08	8.5% Sucrose	Increase sucrose to 8.5% (w/v)

*Control formulation (F0): 0.90 mM CaCl₂, 0.49 mM MgCl₂, 2.68 mM KCl, 1.47 mM KH₂PO₄, 172 mM NaCl, 8.10 mM Na₂HPO₄, 1% (w/v) sucrose, 0.05% (w/v) poloxamer 188 (P188), pH 7.0-7.6.

Results

Formulation Characterization

[0088] To confirm that the correct formulations were achieved, SB-525 DP formulations were tested to determine osmolality, P188 concentration, sucrose concentration, and capsid ratio and purity by reduced CGE. The results to these tests for M05-M08 are shown in **Table 14** below. Capsid purity and ratio showed no significant differences as measured by rCGE. Osmolality is within expected ranges, dependent on the level of sucrose. M05-M08 samples demonstrated the correct concentrations for P188. In addition, concentrations of calcium and magnesium were confirmed by CEDEX to be within expected ranges for all formulations.

Table 14. Formulation Characterization

Material	Osmolality (mOsm/kg)	Sucrose (%)	P188 (µg/mL)	Purity (%Capsid)	AAV Ratio		
					%VP1	%VP2	%VP3
M05 – Control	399	1.10	589	95.2	2.0	3.3	94.7
M06 –Ca Negative	391	1.00	565	95.3	2.1	3.0	94.9
M07 – Ca/Mg Negative	417	1.00	575	95.8	1.7	2.9	95.4
M08 – 8.5% Sucrose	655	8.50	568	95.2	1.8	2.6	95.6

Vector Genome Titer (vg/mL)

[0089] Vector genome titer results for M05-M08 are presented below in **Table 15**. At ≤ -65°C and 2-8°C conditions, there was no significant trend observed after storage for 4 weeks. After 40°C for 3 days, the Ca/Mg negative formulation showed a downward trend in vector genome titer. This result is considered within assay variability, but is consistent with vp titer and UV 260/280 results for this formulation.

Table 15. Genome Titer (vg/mL)

Formulation	Timepoint					
	T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}
-70°C						
M05 - Control	7.44E+12	Not tested				7.77E+12

Formulation	Timepoint					
	T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}
M06 - Ca Negative	7.98E+12					7.47E+12
M07 - Ca / Mg Negative	6.33E+12					6.24E+12
M08 - 8.5% Sucrose	6.23E+12					6.56E+12
5°C						
M05 - Control	7.44E+12	Not tested				7.39E+12
M06 - Ca Negative	7.98E+12					6.95E+12
M07 - Ca / Mg Negative	6.33E+12					6.56E+12
M08 - 8.5% Sucrose	6.23E+12					6.24E+12
25°C						
M05 - Control	7.44E+12	Not tested		7.23E+12	Not tested	7.84E+12
M06 - Ca Negative	7.98E+12			7.41E+12		7.09E+12
M07 - Ca / Mg Negative	6.33E+12			6.04E+12		5.85E+12
M08 - 8.5% Sucrose	6.23E+12			6.11E+12		7.01E+12
40°C						
M05 - Control	7.44E+12	7.16E+12	Not tested			
M06 - Ca Negative	7.98E+12	6.94E+12				
M07 - Ca / Mg Negative	6.33E+12	4.63E+12				
M08 - 8.5% Sucrose	6.23E+12	6.68E+12				

Visible Appearance

[0090] All formulations displayed B9 color and less than or equal to opalescence reference 1, color and clarity standards, respectively, used during visual inspection against a black and white background, for all timepoints and conditions (*see, e.g.*, Ph. Eur. 7.0, 20201, 20202 (01/2008); Millipore Sigma Colour Reference Solutions B). Visible appearance results show that only the “control” formulation (M05) displayed white flake-like particles that were too many to count (TMTC) when held at 25°C for longer than 1 week, or 40°C for 3 days or longer. M06 and M07 formulations did occasionally show TMTC visible particles; however, the particle descriptions for these samples were all fiber-like particles. While these particles were not identified for this study, fiber-like particles are more characteristic of exogenous particles (e.g., filter particles) versus the flake-like particles that are characteristic of calcium phosphate. Also, appearance of fiber-like/exogenous particles is negligible for lab-based development studies where DP is not manufactured under tightly controlled environmental conditions.

Cumulative Sub-Visible Particles

[0091] Sub-visible cumulative particle analysis by the HIAC showed the only formulation with significant sub-visible particle count was the “control” formulation, which showed an increasing trend with more aggressive stability conditions (higher temperatures for longer time). Other

formulations (M06-M08) showed only non-significant particle counts, independent of time or condition.

Functional Bioassay (Potency)

[0092] Functional FVIII bioassay results are presented below in **Table 16**. Results showed no significant changes in potency when samples are kept at either $\leq -65^{\circ}\text{C}$ or $2-8^{\circ}\text{C}$ conditions. At 25°C , there was a downward trend in potency for all formulations (M05-M08) after 4 weeks. At 40°C , there was a significant drop in potency for the Ca/Mg negative formulation after 3 days.

Table 16. Functional Bioassay (Relative Potency)

Formulation	Material	Timepoint					
		T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}
-70°C							
M05 - Control	M05	75	Not tested				81
M06 - Ca Negative	M06	90					81
M07 - Ca / Mg Negative	M07	67					68
M08 - 8.5% Sucrose	M08	74					74
5°C							
M05 - Control	M05	75	Not tested				73
M06 - Ca Negative	M06	90					87
M07 - Ca / Mg Negative	M07	67					71
M08 - 8.5% Sucrose	M08	74					76
25°C							
M05 - Control	M05	75	Not tested	53	Not tested	37	
M06 - Ca Negative	M06	90		66		63	
M07 - Ca / Mg Negative	M07	67		39		41	
M08 - 8.5% Sucrose	M08	74		55		45	
40°C							
M05 - Control	M05	75	51	Not tested			
M06 - Ca Negative	M06	90	60				
M07 - Ca / Mg Negative	M07	67	22				
M08 - 8.5% Sucrose	M08	74	56				

SEC

[0093] SEC results are presented below. Percent aggregate results are shown in **Table 17** below. No significant trend in aggregation was seen at $\leq -65^{\circ}\text{C}$, $2-8^{\circ}\text{C}$, or 25°C stability conditions. At 40°C , there was an increasing trend in aggregates for the Ca/Mg negative formulation, up to 7% HMWS after one week. The “calcium negative” formulation showed approximately 3% HMWS at the end of one week at 40°C . Other formulations did not show

significant growth in aggregation when held at $\leq -65^{\circ}\text{C}$ or $2-8^{\circ}\text{C}$ for up to 5 weeks, 25°C for up to four weeks, and 40°C for up to 1 week.

Table 17. Concentration of Aggregates by SEC (%HMWS)

Formulation	Material	Timepoint						
		T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}	T _{5W}
-70°C								
M05 – Control	M05	NMT 1.0	NT				NMT 1.0	NMT 1.0
M06 – Ca Negative	M06	NMT 1.0					NMT 1.0	NMT 1.0
M07 – Ca / Mg Negative	M07	NMT 1.0					NMT 1.0	NMT 1.0
M08 – 8.5% Sucrose	M08	NMT 1.0					NMT 1.0	NMT 1.0
5°C								
M05 – Control	M05	NMT 1.0	NT		NMT 1.0	NT	NMT 1.0	NMT 1.0
M06 – Ca Negative	M06	NMT 1.0			NMT 1.0		NMT 1.0	
M07 – Ca / Mg Negative	M07	NMT 1.0			NMT 1.0		NMT 1.0	
M08 – 8.5% Sucrose	M08	NMT 1.0			NMT 1.0		NMT 1.0	
25°C								
M05 – Control	M05	NMT 1.0	NT		NMT 1.0	NT	NMT 1.0	NT
M06 - Ca Negative	M06	NMT 1.0			NMT 1.0		NMT 1.0	
M07 - Ca / Mg Negative	M07	NMT 1.0			NMT 1.0		2.6	
M08 - 8.5% Sucrose	M08	NMT 1.0			NMT 1.0		NMT 1.0	
40°C								
M05 – Control	M05	NMT 1.0	NMT 1.0	NMT 1.0	NT			
M06 – Ca Negative	M06	NMT 1.0	3.1	2.6				
M07 – Ca / Mg Negative	M07	NMT 1.0	5.3	7.0				
M08 – 8.5% Sucrose	M08	NMT 1.0	1.9	NMT 1.0				

*NMT: no more than. NT: Not tested.

[0094] Viral particle results are shown below in **Table 18**. All formulations held at $\leq -65^{\circ}\text{C}$, $2-8^{\circ}\text{C}$, or 25°C conditions showed no significant change in viral particle titer. However, at 40°C , there was a significant drop in particle titer for the Ca/Mg negative formulation after 3 days and 1 week. Other formulations (M05-M06, M08) did not show a significant drop in viral particle titer when held at $\leq -65^{\circ}\text{C}$ or $2-8^{\circ}\text{C}$ for up to 5 weeks, 25°C for up to four weeks, and 40°C for up to 1 week.

Table 18. Viral Particle Titer by SEC (vp/mL)

Formulation	Material	Timepoint						
		T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}	T _{5W}
-70°C								
M05 – Control	M05	2.46E+13	NT				2.43E+13	2.54E+13
M06 – Ca Negative	M06	2.44E+13					2.41E+13	2.61E+13
M07 – Ca / Mg Negative	M07	2.02E+13					2.01E+13	2.11E+13
M08 – 8.5% Sucrose	M08	2.13E+13					2.16E+13	2.27E+13
5°C								
M05 – Control	M05	2.46E+13	NT		2.55E+13	NT	2.45E+13	2.51E+13
M06 – Ca Negative	M06	2.44E+13			2.54E+13		2.41E+13	2.62E+13
M07 – Ca / Mg Negative	M07	2.02E+13			2.11E+13		1.99E+13	2.14E+13
M08 – 8.5% Sucrose	M08	2.13E+13			2.25E+13		2.16E+13	2.34E+13
25°C								
M05 – Control	M05	2.46E+13	NT		2.49E+13	NT	2.35E+13	NT
M06 – Ca Negative	M06	2.44E+13			2.53E+13		2.39E+13	
M07 – Ca / Mg Negative	M07	2.02E+13			2.01E+13		1.90E+13	
M08 – 8.5% Sucrose	M08	2.13E+13			2.23E+13		2.11E+13	
40°C								
M05 – Control	M05	2.46E+13	2.23E+13	2.14E+13	NT			
M06 – Ca Negative	M06	2.44E+13	2.16E+13	2.09E+13				

Formulation	Material	Timepoint						
		T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}	T _{5W}
M07 – Ca / Mg Negative	M07	2.02E+13	1.62E+13	1.59E+13				
M08 – 8.5% Sucrose	M08	2.13E+13	2.09E+13	2.06E+13				

[0095] UV 260/280 ratio results are presented in **Table 19** below. For UV 260/280 ratio, there was a recorded downward trend for the Ca/Mg negative formulation when held at 40°C. UV 260/280 is considered a surrogate for empty/full particle ratio. Other formulations (M05, M06, and M08) did not show any significant change in UV 260/280 ratio at any condition or timepoint, as shown.

Table 19. UV 260/280 Ratio by SEC

Formulation	Material	Timepoint						
		T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}	T _{5W}
-70°C								
M05 - Control	M05	1.33	NT				1.33	1.33
M06 - Ca Negative	M06	1.32					1.32	1.33
M07 - Ca / Mg Negative	M07	1.32					1.32	1.33
M08 - 8.5% Sucrose	M08	1.32					1.32	1.33
5°C								
M05 - Control	M05	1.33	NT		1.33	NT	1.32	1.38
M06 - Ca Negative	M06	1.32			1.33		1.33	1.33
M07 - Ca / Mg Negative	M07	1.32			1.33		1.32	1.33
M08 - 8.5% Sucrose	M08	1.32			1.33		1.32	1.33
25°C								
M05 - Control	M05	1.33	NT		1.34	NT	1.33	NT
M06 - Ca Negative	M06	1.32			1.32		1.33	
M07 - Ca / Mg Negative	M07	1.32			1.33		1.33	
M08 - 8.5% Sucrose	M08	1.32			1.32		1.32	
40°C								
M05 - Control	M05	1.33	1.33	1.33	NT			
M06 - Ca Negative	M06	1.32	1.32	1.32				
M07 - Ca / Mg Negative	M07	1.32	1.28	1.25				
M08 - 8.5% Sucrose	M08	1.32	1.33	1.33				

pH

[0096] There were no significant changes in pH at any condition and timepoint for all formulations, as shown in **Table 20** below.

Table 20. pH

Formulation	Material	Timepoint						
		T ₀	T _{3D}	T _{1W}	T _{2W}	T _{3W}	T _{4W}	T _{5W}
-70°C								
M05 - Control	M05	7.3	NT				7.2	7.3
M06 - Ca Negative	M06	7.3					7.3	7.3
M07 - Ca / Mg Negative	M07	7.3					7.3	7.4
M08 - 8.5% Sucrose	M08	7.2					7.3	7.3
5°C								
M05 - Control	M05	7.3	NT	7.3	NT	7.2	7.3	
M06 - Ca Negative	M06	7.3		7.3		7.3	7.3	
M07 - Ca / Mg Negative	M07	7.3		7.2		7.3	7.3	
M08 - 8.5% Sucrose	M08	7.2		7.2		7.2	7.2	
25°C								
M05 - Control	M05	7.3	NT	7.3	NT	7.2	NT	
M06 - Ca Negative	M06	7.3		7.3		7.3		
M07 - Ca / Mg Negative	M07	7.3		7.3		7.2		
M08 - 8.5% Sucrose	M08	7.2		7.2		7.2		
40°C								
M05 - Control	M05	7.3	7.1	7.1	NT			
M06 - Ca Negative	M06	7.3	7.3	7.3				
M07 - Ca / Mg Negative	M07	7.3	7.3	7.3				
M08 - 8.5% Sucrose	M08	7.2	7.1	7.2				

Mass Spectrometry Characterization (Deamidation)

[0097] Deamidation results as determined by mass spectrometry are presented below in **Table 21**. Only samples stored at 40°C were used for this testing as samples stored at lower temperatures are not expected to show significant differences between formulations over the 5-week study period.

[0098] Results are presented using the T₀ of the control formulation as the T₀ of all formulations. Among all the deamidation sites, the N57G and N94H hotspots in AAV VP1 are the two which showed the most significant increase in deamidation over 3 weeks at 40°C. Other sites also showed an increase of deamidation, but to a much lesser extent (not shown). These two hotspots are especially important, as they are expected to affect transduction efficiency. The Ca/Mg negative formulation showed the most significant increase in deamidation. The other

formulations (M05, M06, and M08) all had similar levels of deamidation increase after 3 days and 3 weeks at 40°C.

Table 21. Deamidation by Mass Spectrometry (% at 40°C)

Formulation	Material	Timepoint					
		N57G (VP1)			N94H (VP1)		
		T ₀ *	T _{3D}	T _{3W}	T ₀ *	T _{3D}	T _{3W}
M05 - Control	M05	7.8	14.4	41.1	5.1	6.7	30.4
M06 - Ca Negative	M06	7.8	18.6	43.5	5.1	6.4	33.9
M07 - Ca / Mg Negative	M07	7.8	23.1	57.4	5.1	8.6	54.6
M08 - 8.5% Sucrose	M08	7.8	16.0	38.7	5.1	6.0	23.7

*T₀ was tested on M05 material and used as T₀ for all formulations.

Conclusions

[0099] Three possible variations on the current SB-525 formulation were evaluated: one with no calcium, one with neither calcium nor magnesium, and one with a higher concentration of sucrose. Examples 1 and 2 show the random generation of very many white-flake particles appearing in both buffer and drug product, especially after freeze/thaw cycling followed by being kept on stability at either 25°C for longer than 1 week, or 40°C for 3 days or longer. The particles were identified as calcium phosphate.

[0100] The results here demonstrate that calcium chloride is a non-essential excipient for product stability at intended and stressed storage conditions. Additionally, no significant difference was observed for “calcium negative” and “high sucrose” formulations for up to 2 weeks at 40°C, 4 weeks at 25°C, and 5 weeks at 5°C and -70°C. However, it was observed that removal of both calcium and magnesium from the formulation resulted in changes in drug product quality attributes, including showing larger drops in vg and vp titer as well as higher deamidation and aggregation, especially when kept at 40°C. In addition, it was found that through 5 weeks, only the previous (control) formulation continued to demonstrate the white flake-like particles.

Example 4: Further Reformulation of SB-525

[0101] In order to prevent particle generation, three types of changes to the formulation were tested in this Example: (1) increasing the sucrose concentration from 1% to 5-10% to increase stability against FT stress, (2) removing the divalent cations to remove the source of the particles

and prevent potential solubility issues, and (3) increase NaCl to shift the ionic strength of the formulation.

[0102] More specifically, the experiments in this Example assessed the stability of SB-525 buffer when reformulated to one of several variants in comparison to the previous (control) formulation; that is, 172 mM NaCl, 8.10 mM Na₂HPO₄, 2.68 mM KCl, 1.47 mM KH₂PO₄, 0.90 mM CaCl₂, 0.49 mM MgCl₂, 1% (w/v) sucrose, and 0.05% (w/v) poloxamer 188, pH 7.0-7.6. Formulations were filled at 5 mL into 6 mL AT vials, subjected to 5 uncontrolled FT cycles ($\leq$ -65°C to ambient), and then placed on thermal stability at 2-8°C (accelerated; liquid storage) and 25°C (stressed; liquid storage) to evaluate the various buffers against particle formation.

Study Design

[0103] Formulations tested, as shown in **Table 22**, were formulated by addition of sodium and potassium chlorides and phosphates to water, followed by addition of sucrose. If present, magnesium chloride, followed by calcium chloride, were then prepared in separate 50 mL solutions, transferred to the larger solution. Poloxamer 188 was then added to the solution. The formulations were then QS'd (quantum satis), pH tested, and filtered over a 0.22 μ m PES filter.

Table 22. Formulations

Material	Formulation	Difference from Control
0139-M03	200 mM NaCl	Increase NaCl to 200 mM
0139-M04	5% sucrose	Increase sucrose to 5%
0139-M05	8.5% sucrose	Increase sucrose to 8.5%
0139-M06	10% sucrose	Increase sucrose to 10%
0139-M07	No CaCl ₂	Removed CaCl ₂
0139-M08	No MgCl ₂ or CaCl ₂	Removed CaCl ₂ and MgCl ₂
0139-M09	Control	N/A

[0104] With these formulations, the AT vials were filled at 5 mL, subjected to 5 uncontrolled freeze/thaw cycles, and then placed on either 5°C or 25°C stability. The stability pull schedule is outlined in **Table 23**. In the Table, X refers to appearance (liquid); A refers to osmolality (freezing point depression), conductivity, viscosity, and density; B refers to light obscuration with HIAC; C refers to P188 concentration; and D refers to pH.

Table 23. Stability Schedule 0139-M03 to -M08

Temp (°C)	T ₀	FT1	FT2	FT3	FT4	FT5*	T _{5D}	T _{8D}	T _{2W}	T _{3W}	T _{4W}	T _{6W}	T _{8W}
5 (± 3)	XABD	X	X	XBD	X	XBD	X	X	XC	XB	XB	XB	XB
25 (± 3)							XBC		X				

* The 5 FT sample was the T₀ for the thermal stability samples.

Formulation Characterization

[0105] SB-525 buffer formulations were tested to determine conductivity, osmolality, density, and viscosity. P188 concentration was also measured at 2.5 weeks of 5°C storage, and 5 days of 25°C. The results to these tests are shown in **Table 24** below. The results in conductivity, osmolality, density, and viscosity for M03-M09 all follow expected trends – higher amounts of sucrose resulted in a higher osmolality, density, and viscosity; higher NaCl resulted in a higher osmolality and conductivity. Results for the concentration of P188 were within method variability for each set of results, confirming the correct P188 concentration was achieved during formulation.

Table 24. Formulation Characterization

Formulation	Conductivity (ms/cm)	Osmolality (mOsm/kg)	Density ¹ (g/mL)	Viscosity ² (Cp)	P188 (µg/mL)	
					T _{2.5W} 5°C	T _{5D} 25°C
M03 – 200 mM NaCl	20.20	433	1.011915	1.165	590	484
M04 – 5% Sucrose	16.12	515	1.026105	1.285	630	467
M05 – 8.5% Sucrose	15.37	647	1.039606	1.382	635	486
M06 – 10% Sucrose	15.12	704	1.045258	1.429	633	457
M07 – Ca Negative	17.91	380	1.010685	1.112	663	488
M08 – Ca / Mg Negative	17.88	379	1.010806	1.123	672	471
M09 – Control	17.86	384	1.010854	1.105	668	475

¹ Temperature during density measurement was recorded as 20.0°C.

² Temperature during viscosity measurement was recorded as 20.0°C and shear rate was recorded as 2000 s⁻¹.

pH

[0106] No significant change in pH was observed for any formulation during FT cycling, as shown below in **Table 25**.

Table 25. pH Results

Formulation	FT Cycle		
	T ₀	FT3	FT5
M03 – 200 mM NaCl	7.2	7.3	7.2
M04 – 5% Sucrose	7.2	7.2	7.2
M05 – 8.5% Sucrose	7.2	7.2	7.2
M06 – 10% Sucrose	7.1	7.2	7.2
M07 – Ca Negative	7.3	7.3	7.3
M08 – Ca and Mg Negative	7.3	7.3	7.3
M09 – Control	7.2	7.3	7.2

Visible Appearance

[0107] All samples displayed B9 color and less than or equal to opalescence reference 1 for each condition and timepoint tested. Visible appearance results showed that only the control formulation (M09) consistently displayed too many to count (TMTC), white flake-like particles from 5 days to up to 8 weeks at 5°C and 25°C. The 5% sucrose formulation exhibited random generation of TMTC visible particles. Many samples also showed 1-5 fibrous particles. While these particles were not identified for this study, fiber-like particles are more characteristic of exogenous particles (e.g., filter particles) versus the flake-like particles that are characteristic of calcium phosphate. Also, appearance of fiber-like/exogenous particles was negligible for lab-based development studies where DP is not manufactured under tightly controlled environmental conditions.

Sub-Visible Particle Count

[0108] Sub-visible particle analysis by the HIAC showed the only formulation with significant and consistent sub-visible particle count was the control formulation (M09), exacerbated by ongoing storage at a higher stability condition (25°C). Other formulations (M03-M08) showed non-significant particle counts, independent of time or condition, and demonstrated no overall trend.

Conclusions

[0109] This Example evaluated the effects of freeze-thaw stress and thermal stability on several formulation variants from the previous (control) SB-525 formulation. Seven different formulations were filled into AT crystal closed vials, freeze-thaw cycled, and stored at 5°C and 25°C for 8 weeks. Across all study conditions, only the control formulation continued to demonstrate the white flake-like particles consistently.

[0110] After FT cycling, no formulation exhibited significant visible particles formation or changes in pH, and thus all formulations were placed on short-term stability at 5°C and 25°C over a period of 8 weeks. Upon placing on stability, the only formulation shown to consistently generate significant visible particles was the control formulation (M09). Although the particle results were comparable (i.e., no significant visible particle generation), the “200 mM NaCl” (M03), “5% sucrose” (M04), and “10% sucrose” (M06) formulations were not selected for continued reformulation studies. Particularly, the “5% sucrose” formulation (M04) exhibited some formation of white flake-like particles, indicating that this concentration of sucrose may not be sufficient to prevent particle generation due to FT stress, and “10% sucrose” (M06) would introduce manufacturing challenges due to its higher viscosity. Therefore, based on these results, the “8.5% sucrose” (M05), “calcium negative” (M07), and “calcium and magnesium negative” (M08) formulations appear promising.

Example 5: Final Formulation for SB-525

[0111] The composition and description of SB-525 (PF-07055480) Drug Substance (DS) is shown in **Table 26**. The formulation had a final pH of 7.3 ± 0.3 . Excipient concentration was obtained wholly or in part through the addition of the base buffer (Phosphate Buffered Saline). DS concentration target was $1.0\text{E}+13$ vg/mL ($0.5\text{E}+13$ – $2.5\text{E}+13$ vg/mL), with a DS range of 50-250% of DS target.

Table 26. SB-525 Drug Substance Formulation Description

Raw Material	Chemical Formula	FW	Concentration (mM)	Concentration (g/L)
SB-525	N/A	N/A	$1.0\text{E}+13$ vg/mL	$1.0\text{E}+13$ vg/mL
Magnesium Chloride Hexahydrate	$\text{MgCl}_2 \bullet 6\text{H}_2\text{O}$	203.30	0.49	0.10
Potassium Chloride	KCl	74.5513	2.68	0.20

Raw Material	Chemical Formula	FW	Concentration (mM)	Concentration (g/L)
Potassium Phosphate Monobasic	KH ₂ PO ₄	136.086	1.47	0.20
Sucrose	C ₁₂ H ₂₂ O ₁₁	342.2965	1% (w/v)	10.00
Sodium Chloride	NaCl	58.44	172	10.05
Poloxamer 188 (P188)	(C ₃ H ₆ O • C ₂ H ₄ O) _x	8350	0.05% (w/v)	0.50
Sodium Phosphate Dibasic Anhydrous	Na ₂ HPO ₄	141.96	8.10	1.15
WFI	H ₂ O	18.015	q.s. to 1 mL	q.s. to 1 mL

[0112] The composition and description of SB-525 (PF-07055480) Drug Product is shown in **Table 27**. The DP had a final pH of 7.3 ± 0.3 . Excipient concentration was obtained wholly or in part through the addition of the base buffer (Phosphate Buffered Saline). DP concentration target was $1.0\text{E}+13$ vg/mL ($0.3\text{E}+13 - 3.0\text{E}+13$ vg/mL), with a DP range of 30-300% of DP target.

Table 27. SB-525 Drug Product Formulation Description

Name of Ingredients	Function	Concentration (mM)	Unit Formula (mg/mL)	Unit Formula (mg/vial)
SB-525	Active Ingredient	$1.0\text{E}+13$ vg/mL	$1.0\text{E}+13$ vg/mL	$6.0\text{E}+13$ vg/vial
Sodium Phosphate Dibasic Anhydrous	Buffering Components	8.10	1.15	6.75
Potassium Phosphate Monobasic		1.47	0.20	1.20
Sodium Chloride	Stabilizers	172	10.05	60.30
Potassium Chloride		2.68	0.20	1.20
Magnesium Chloride Hexahydrate		0.49	0.10	0.60
Sucrose	Cryoprotectant	1% (w/v)	10.00	60.00
Kolliphor (Poloxamer) P 188	Surfactant	0.05% (w/v)	0.50	3.00
WFI	Solvent	q.s. to 1 mL	q.s. to 1 mL	q.s. to nominal fill volume

Container and Fill Volume

[0113] Filtered Drug Substance was packaged in sterile high-density polyethylene (HDPE) bottles. The DP was filled into AT 10 mL cyclo-olefin copolymer (COC) vials with in-place thermoplastic elastomer stoppers (Aseptic Technologies VIA-101800). Both DS and DP were

stored at -60°C to -90°C. Each vial contained 6.4 mL of DP (intended extractable volume 6 mL), with 6.4E+13 (nominal 6.0E+13) vg SB-525 AAV.

Characterization of DP

[0114] The viscosity, osmolality, density, and conductivity of the SB-525 DP were measured. The density was 1.0106 g/mL (20°C). The viscosity was 1.112 cP (20°C). The osmolality was 374 mOsm/kg. The conductivity was 17.80 mS/cm (20°C).

Example 6: AAV6 Viral Vector Drug Product Formulations

[0115] Examples 6-8 below describe an additional reformulation and accelerated stability study performed to evaluate AAV2/6 viral vector drug product formulations containing various concentrations of divalent cation salts. As in the previous example, the viral vector has an AAV6 capsid and a recombinant genome containing AAV2 ITRs. The viral vector here carries a transgene that encodes alpha-L-iduronidase (IDUA). This transgene would help patients who is IDUA-deficient, such as patients with mucopolysaccharidosis type I (MPS I), also known as Hurler Syndrome (a lysosomal storage disorder). The AAV genome is shown as sequence No. 28 in Table 5 of US2020/0246486. Because the viral genome is located within the AAV capsid and not exposed to the product formulation, the observations made in Examples 6-8, like those in the previous examples, are expected to be applicable to AAV6 vectors that carry other transgenes.

[0116] The study also was performed to identify a new product formulation that does not form precipitates following freeze/thaw cycles. The stability of four AAV6 viral vector drug product formulations containing various concentrations of divalent cation salts was assessed.

[0117] The formulations tested contained various concentrations of divalent cation salts (Ca^{2+} and Mg^{2+}). As described above, prior AAV6 formulations as well as formulation buffer without AAV6 were all observed to form small amounts of visible precipitates following multiple freeze/thaw cycles. The precipitated particles were determined to be comprised of calcium phosphate salts. Since the drug product will experience freeze/thaw cycles during typical use, the chance of salt precipitation would pose a risk to patient safety as well as a risk to product quality. The study shown in Examples 6-8 below aimed to find improved formulations that do not have such a precipitation issue.

[0118] In the study, samples of AAV6 viral vector product were prepared in different product formulations by tangential flow filtration and spiking samples with higher concentration “spike buffers.” The reformulated samples were then incubated at various accelerated stability conditions, and the samples’ quality attributes were evaluated following incubation. Quality attribute results were assessed with consideration for known method variability where appropriate. Outliers and trending results over the study duration were identified for each of the four formulations. A scoring of Pass, Neutral, or Fail was assigned for each quality attribute and formulation based on the results at each study endpoint. Finally, the overall quality attribute stability scorings of each four formulations were compared against each other. The study is described in detail below.

Sample Preparation

[0119] AAV6 product formulations prepared herein contained AAV6 donor vector at approximately $1.0\text{E}+13$ vg/mL suspended in formulation buffer F0 as described in Table 1 below. Buffer F0 is based upon a recipe of Dulbecco’s phosphate buffered saline that includes divalent cations calcium (as CaCl_2) and magnesium (as MgCl_2), approximately 35 mM additional sodium chloride, and is formulated to 1% w/v sucrose and 0.05% w/v poloxamer 188.

[0120] In order to transfer the AAV6 material into alternate buffer formulations, buffer exchange by tangential flow filtration was performed as shown in **FIG. 2**. Briefly, several vials of the AAV6 drug product formulated in buffer F0 were thawed and transferred to a single Ultrafiltration/Diafiltration (UF/DF) reservoir. Ultrafiltration was first performed to concentrate the material approximately 2x. Then the concentrated material was diafiltered with at least 10x equivalent volumes of formulation buffer F1. The recovered intermediate material, labeled “A” in **FIG. 2**, should thus contain approximately $2.0\text{E}+13$ vg copies/mL suspended in formulation buffer F1.

[0121] The intermediate UF/DF product “A” was then separated into three volumes and formulated into three different buffers. Three additional formulation buffers (F1, F2, and F3; **Table 28**) were derived from Dulbecco’s phosphate buffered saline with additional sodium chloride, sucrose, and poloxamer 188 (e.g., Pluronic® F-68). These three buffers contained no calcium and instead had different amounts of magnesium. Buffer F1 contained no calcium or magnesium components, Buffer F2 contained the equivalent molar concentration of magnesium

as F0, and Buffer F3 contained additional magnesium accounting for the moles of calcium removed from buffer F0.

Table 28. Composition of Formulation Buffers

Component (unit)	F0	F1	F2 (6x conc)	F2 (1x conc)	F3 (6x conc)	F3 (1x conc)
NaCl (mM)	171.8	171.8	171.8	171.8	171.8	171.8
KCl (mM)	2.7	2.7	2.7	2.7	2.7	2.7
Na ₂ HPO ₄ (mM)	8.1	8.1	8.1	8.1	8.1	8.1
KH ₂ PO ₄ (mM)	1.5	1.5	1.5	1.5	1.5	1.5
CaCl ₂ (mM)	0.9	0.0	0.0	0.0	0.0	0.0
MgCl ₂ (mM)	0.5	0.0	3.0	0.5	8.4	1.4
Sucrose (% w/v)	1.00%	1.00%	1.00%	1.00%	1.00%	1.00%
Poloxamer 188 (% w/v)	0.05%	0.05%	0.05%	0.05%	0.05%	0.05%
Target pH	7.1-7.5					

[0122] To simplify sample preparation and to allow preparation of different buffers, 6-times higher concentrated “spike buffers” of buffers F2 and F3 were prepared. As shown in **FIG. 3**, these F2 and F3 “6x conc” buffers when mixed at a 1:5 ratio with F1 yielded the intended composition of buffers F2 and F3, respectively.

[0123] To prepare these formulation buffers, individual dry components were weighed off using a microbalance. The components were mixed and dissolved with deionized water for injection. These buffers were then titrated with 0.1 M NaOH or 0.1 M HCl to the intended pH range if needed. Finally, these buffers were formulated with sucrose and poloxamer 188 to the desired concentrations.

[0124] The compositions of the prepared drug product formulations were measured with several semiquantitative assays as a check, the results of which are reported in **Table 29**. Off-the-shelf colorimetric assays were used to measure concentrations of Ca²⁺ (Bio Vision Cat# K380-250) and Mg²⁺ (Bio Vision Cat#K385-1 00). For both colorimetric assays, the sample concentrations were within the assays’ dynamic linear ranges, and the reported signals and calculated concentrations trended well with the theoretical sample compositions. Critically, the calcium signals for formulations F1, F2, and F3 all matched the assay negative controls. Thus, these samples contained no calcium, and the TFF sample preparation step was effective at removing any calcium that was present in the F0 starting material. The magnesium assay also

confirmed Mg^{2+} was also removed by TFF and spiked into the appropriate concentrations in F2 and F3.

Table 29. Experimentally Measured Parameters of Formulated Drug Products

Component (unit)	F0	F1	F2 (1x conc)	F3 (1x conc)
CaCl_2 (mM, by colorimetric assay)	1.02	0.07	0.09	0.1
MgCl_2 (mM, by colorimetric assay)	0.29	-0.04	0.38	0.9
VG titer (vg/ml, by qPCR)	1.54E+13	1.77E+13	1.91E+13	1.87 E+13
Particle Concentration (p/mL, by MADLS)	7.79E+12	6.38E+12	7.30E+12	8.23E+12

*MADLS: Multi-Angle Dynamic Light Scattering.

[0125] qPCR was also performed to measure vg titer, and multi-angle dynamic light scattering (MADLS) was performed to measure particle concentration. Again, these results were in the expected ranges from sample preparation, indicating that the buffer exchange and formulation steps performed as intended.

[0126] The bulk formulated products were sterile filtered and filled at 0.5 mL/vial into 2 mL cyclic olefin polymer (COP) vials (West Pharma/Daikyo CZ Cat # 19550057).

Sample Incubation

[0127] Vial drug products were incubated at various conditions described below.

Freeze/thaw cycling was performed with pull dates listed in **Table 30**.

Table 30. Freeze/Thaw Cycling Sample Pull Dates

Condition	Start Date	3X Cycles	5X Cycles	10X Cycles
Freeze/Thaw cycling -80°C/Ambient	D0	D2	D4	D11

[0128] Samples were subject to “accelerated, stressed” conditions (40°C/75% relative humidity (RH)) or to “accelerated, ambient” conditions (25°C/60% RH), with pull dates at D3, D7, 2 weeks, 1 month, 2 months, 3 months, or 6 months. Samples were stored at 2-8°C and analyzed within 24 hours of their pull time.

[0129] All pulled samples were aliquoted into polycarbonate flip-top centrifuge tubes for the intended sample testing. Aliquots were stored at 2-8°C during active testing for no longer than 2 months. If testing was not performed within a reasonable time from the pull date, the aliquots

were frozen at $\leq -65^{\circ}\text{C}$ until testing could occur. All retain samples and remaining materials following testing were frozen at $\leq -65^{\circ}\text{C}$ for long term storage.

Example 7: Testing of AAV6 Drug Product Formulations

[0130] Sample testing performed included the quality attributes listed in **Table 31**.

Abbreviations are shown as below: DLS, dynamic light scattering; MADLS, multi-angle dynamic light scattering; HMWS, high molecule weight species; SE-LC, size exclusion liquid chromatography; and AEX-LC, anion exchange liquid chromatography. Appearance of the solutions was assessed to confirm that they were clear, colorless, and free of particulates. A solution that was hazy, cloudy, or containing visible particles did not meet the criteria.

Table 31. Product Quality Attributes Evaluated

Category	Quality Attribute	Testing Methods
General	Appearance, Liquid	Visual inspection
	pH	Potentiometric
Purity	Monomer Peak Mean Size	DLS
	Polydispersity Index	DLS
	Monomer Fraction	DLS
	HMWS Fraction	DLS
	HMWS Fraction	SE-LC
	% Full Capsids	AEX-LC
Strength	Vector Genome Titer	qPCR
	Infectious Titer	TCID ₅₀
	VG/TCID ₅₀ Ratio	Calculation
	Capsid Concentration	ELISA
	Monomer Concentration	SE-LC
	Monomer Concentration	MADLS

Initial Samples

[0131] Quality attribute results from all initial formulated drug product samples are shown in **Table 32** and **Table 33**. Results are grouped by the quality attribute categories of general, purity, and strength.

Table 32. General and Purity Quality Attribute Results of Initial (t₀) Samples

Formulation	F0	F1	F2	F3
Appearance (Pass/Fail)	Pass	Pass	Pass	Pass
pH	7.3	7.3	7.2	7.2

Monomer Peak Mean Size (nm)	29.7	33.0	33.6	33.4
Polydispersity Index	0.07	0.12	0.14	0.12
% Monomer, DLS	100.0%	100.0%	100.0%	100.0%
% HMWS, DLS	0.00%	0.00%	0.00%	0.00%
% HMWS, SE-LC	0.2%	0.5%	0.5%	0.4%
% Full Capsids	89.2%	89.1%	89.3%	89.1%

Table 33. Strength Quality Attribute Results of Initial (t₀) Samples

Formulation	F0	F1	F2	F3
VG Titer (vg/mL)	7.9E+12	8.3E+12	9.4E+12	7.7E+12
Infectious Titer (TCID ₅₀ /mL)	9.3E+09	9.3E+09	1.1E+10	1.1E+09
VG/TCID ₅₀	1200	1100	1100	8400
Capsid Titer (capsids/mL)	5.0E+12	5.5E+12	5.2E+12	6.7E+12
Monomer Conc, SE-LC (particles/mL)	9.9E+12	9.5E+12	9.9E+12	9.7E+12
Monomer Conc, MADLS (particles/mL)	7.8E+12	6.4E+12	7.3E+12	8.2E+12

[0132] The initial infectious titer result was usually low for F3 when compared against the other initial samples. This also resulted in a much higher vg/TCID ratio than the other samples. This was attributed primarily to the variability of the TCID₅₀ assay. None of the other results appeared to be substantially affected.

Freeze/Thaw Cycled Samples

[0133] Test results from freeze/thaw cycling of the four different formulations are shown in **FIGs. 4A-D**. The data show that the freeze/thaw cycling did not affect solution pH, monomer capsid size, sample size distribution, or full capsid content; nor did it generate significant amounts of HMWS or soluble aggregates in all four formulations. Freeze/thaw cycling did, however, lead to visible appearance failures in the initial F0 control formulations. Following 5x F/T cycles, small white flecks of precipitates could be observed, and these were characteristic of the calcium phosphate precipitates previously observed. These precipitates were not detected in formulations F1, F2, or F3. The data also show that freeze/thaw cycling also did not appear to significantly affect any product strength attributes when the variability of test methods is also considered.

25°C/60% RH (Ambient) Accelerated Samples

[0134] Test results from ambient condition (25°C/60% RH) incubation of the four different formulations are shown in **FIGs. 5A-D**. The data show that appearance and pH were not

affected by the 25°C condition. The sample size distribution appeared to broaden, increasing the polydispersity index (PDI), and the monomer peak mean size grew slightly as the incubation time increased. High weight molecular species (HMWS) also began to form over incubation time. In general, these HMWS were detected more readily by SE-LC than by DLS. Charge separation of full and empty capsids appears to have been lost following 1-2 months of incubation at 25°C, thus the % full capsids could not be measured by AEX-LC. Capsid titer and monomer concentration were not affected by the 25°C condition, nor did the vg titer appear to be affected. TCID₅₀ decreased at the 3-month and 6-month time point for F0, F1, and F2 but the same result was not observed with F3.

40°C/75% RH Stressed Samples

[0135] Test results from stressed condition (40°C/75% RH) incubation of the four different formulations are shown in **FIGs. 6A-D**. The data show that the 40°C/75% RH condition had a much greater impact on several product quality attributes. The particle size distribution broadened substantially and HMWS were forming. SE-LC appeared to be more sensitive to detecting smaller amounts of HMWS than DLS, but when large amounts of HMWS (and possibly larger molecular weight species) were present, these particles might not have been detected by SE-LC. It is likely that large molecular weight species were being filtered or not passing through the LC column to reach the detector in these cases.

[0136] Following 3 months at 40°C, all solutions began to appear hazy, possibly due to the formation of large insoluble aggregates or HMWS. The solution pH did not appear to be affected. TCID₅₀ did decrease substantially in all samples after 1 month at 40°C/75% RH with the smallest reduction from initial seen in F3.

Example 8: Study Endpoint Assessment

[0137] An intra-sample analysis was performed for each formulation. Within each formulation, each study endpoint result for each quality attribute was scored against the acceptance and failure criteria as described in **FIG. 7**. The intended stability study endpoints were as follows: 10x freeze/thaw cycles of no less than 12 hours at $\leq -65^{\circ}\text{C}$ and no less than 6 hours at ambient temperature per cycle, 3 months at 25°C/60% RH, and 1 month at 40°C/75% RH. At each study endpoint, the quality attributes as listed in **FIG. 7** were determined based on

known and established method variability as well as a holistic assessment of all data generated in this study.

[0138] To perform the inter-sample analysis or a relative assessment of each formulation, each endpoint score for each quality attribute was compared by formulation. When considering a single quality attribute, an overall Pass, Neutral, or Fail scoring was assigned for each formulation by holistically comparing the relative endpoint scorings across the four considered formulations. For example, if all endpoint results had passed acceptance criteria for a given formulation, an overall Pass score was assigned for that quality attribute for that formulation. The number of neutral and failing endpoint conditions were considered when assigning an overall quality attribute scoring for that formulation. For certain quality attributes such as appearance, one failing endpoint score was enough to score an overall Fail for that formulation. For other quality attributes such as monomer concentration, one failing endpoint at the 40°C condition was encountered for all formulations (except F3); thus, this failing endpoint was not scored as severely. TCID₅₀ results were included for information only and a scoring was not assigned.

[0139] These intra-sample analysis scores are shown in **FIG. 8** and **FIG. 9**. A summary table of all overall quality attribute scores for each formulation is shown in **Table 34**, where formulation F0 is used as a control.

Table 34. Inter-Sample Formulation Assessment Summary

Test (method)	F0	F1	F2	F3
Appearance, Liquid (Visual Inspect)	Fail	Pass	Pass	Pass
pH (Potentiometric)	Pass	Pass	Pass	Pass
Size Distribution (DLS)	Neutral	Fail	Neutral	Neutral
HMWS Fraction (DLS)	Pass	Fail	Pass	Pass
HMWS Fraction (SE-LC)	Neutral	Fail	Neutral	Pass
% Full Capsids (AEX-LC)	Pass	Pass	Pass	Pass
VG Titer (qPCR)	Pass	Fail	Pass	Neutral
Capsid Conc. (ELISA)	Pass	Neutral	Pass	Pass
Monomer Conc (SE-LC)	Neutral	Neutral	Neutral	Pass
Monomer Conc. (MADLS)	Neutral	Neutral	Neutral	Pass

[0140] The overall quality attribute scorings over the duration of the accelerated stability study demonstrate that Formulations F3 and F2 are superior to F0 and F1. Formulation F3 appears to have performed the best, with eight overall passing quality attribute scores and only two neutral scores. Formulation F2 also performed well. F0 had an overall failing score for appearance, confirming the initial goal for improving this product formulation. F1 appeared to have the greatest amount of aggregation with the greatest amount of HMWS detected.

Example 9: Extended Temperature Tests

[0141] Stability of SB-525 (PF-07055480) drug product provided at 1.00E+13 vg/mL in formulation buffer was tested at extended temperatures. The formulation buffer contained the following ingredients: 0.49 mM MgCl₂, 2.68 mM KCl, 1.47 mM KH₂PO₄, 172 mM NaCl, 8.10 mM Na₂HPO₄, 1% (w/v) sucrose, 0.05% (w/v) poloxamer 188, pH 7.4.

[0142] Vials containing the drug product were stored at (i) -70°C for 0 days (T₀), (ii) at -150°C for 3 days (T_{3-Days}), and (iii) at -150°C for 14 days (T_{14-Days}). Drug product samples were then analyzed for (i) appearance (liquid), (ii) reduced CE-SDS, (iii) SEC titer_{260/280}, and (iv) *in vitro* FVIII activity (bioassay). The formulation buffer sample was also analyzed for (i) container closure integrity.

[0143] As shown in **Table 35** below, there was no significant change in color, clarity, reduced CE-SDS, SEC titer_{260/280} (a surrogate measure for empty:full capsid ratio), or biological activity (% relative potency) when the samples were stored at the tested conditions including storage at -150°C for up to fourteen days. No impact on container closure integrity was observed after fourteen days storage at -150°C.

Table 35. Stability Results

Test		T ₀	T _{3-Days}	T _{14-Days}
Appearance, Liquid	Color	<=B9	<=B9	<=B9
	Clarity	<= Ref. I	<= Ref. I	<= Ref. I
	Visible Particles	EFVP	EFVP	EFVP
Container Closure Integrity		N.T.	N.T.	Pass
Capsid Protein Purity (CE): % Capsid		95.0	94.5	94.9

Test	T ₀	T _{3-Days}	T _{14-Days}
Capsid Protein Purity (CE): % Other	5.0	5.5	5.1
Size Distribution (SEC): % Monomer	98.8	99.0	99.5
Size Distribution (SEC): % Aggregates	1.2	NMT 1.0	NMT 1.0
Particle Content (SEC): 260/280 Ratio	1.34	1.34	1.33
<i>in vitro</i> FVIII Activity/ Functional Bioassay (% Relative Potency)	67%	69%	70%

EFVP: Essentially Free of Visible Particles

TMTC: Too many to Count

N.T.: Not tested

Example 10: Shipping Simulation and Extended Temperature Tests

[0144] Stability of the SB-525 drug product under simulated shipping conditions, such as shock, pressure, drop, and vibration, was tested. The SB-525 drug product was provided at 1.00E+13 vg/mL in formulation buffer containing the following ingredients: 0.49 mM MgCl₂, 2.68 mM KCl, 1.47 mM KH₂PO₄, 172 mM NaCl, 8.10 mM Na₂HPO₄, 1% (w/v) sucrose, 0.05% (w/v) poloxamer 188, pH 7.4.

[0145] Test sample vials containing the drug product underwent concurrently applied transport hazards (e.g., shock, pressure, drop, and vibration), utilizing a worst-case global transportation profile. Control sample vials were not subjected to those concurrently applied transport hazards. As part of the simulation, test vials were held for 40 hours at -35°C and subsequently for another 40 hours at -70°C. After simulation, control and test drug product vials were stored at -70°C and tested at 0 days (T₀), 6 months (T_{6-Months}), and 10 months (T_{10-Months}). Formulation buffer vials were stored at -70°C and tested at T₀. Drug product samples were analyzed for (i) appearance (liquid), (ii) reduced CE-SDS, (iii) SEC titer_{260/280}, and (iv) *in vitro* FVIII activity (bioassay). Formulation buffer samples were analyzed for (i) container closure integrity.

[0146] As shown in **Table 36** below, there was no significant change in color, clarity, reduced CE-SDS, SEC titer_{260/280} (a surrogate measure for empty:full capsid ratio), or biological activity (% relative potency) when the samples were stored at the tested conditions for up to ten months. There was no impact on container closure integrity at T₀.

Table 36. Stability Results

Test		Sample	T ₀	T _{6-Months}	T _{10-Months}
Appearance, Liquid	Color	Control	<=B9	<=B9	<=B9
		Test	<=B9	<=B9	<=B9
	Clarity	Control	<= Ref. I	<= Ref. I	<= Ref. I
		Test	<= Ref. I	<= Ref. I	<= Ref. I
	Visible Particles	Control	EFVP	EFVP	EFVP
		Test	EFVP	EFVP	EFVP
Container Closure Integrity		Control	Pass	N.T.	N.T.
		Test	Pass	N.T.	N.T.
Genome Titer (qPCR)		Control	1.11E+13	1.02E+13	7.96E+12
		Test	9.07E+12	9.29E+12	7.81E+12
Capsid Titer (ELISA)		Control	1.71E+13	1.28E+13	1.30E+13
		Test	1.69E+13	1.19E+13	1.34E+13
Capsid Protein Purity (CE): % Capsid		Control	94.0	94.3	95.0
		Test	94.5	94.6	94.7
Capsid Protein Purity (CE): % Other		Control	6.0	5.7	5.0
		Test	5.5	5.4	5.3
Size Distribution (SEC): % Monomer		Control	99.2	99.1	99.3
		Test	99.3	98.8	99.4
Size Distribution (SEC): % Aggregates		Control	NMT 1.0	NMT 1.0	NMT 1.0
		Test	NMT 1.0	1.2	NMT 1.0
Particle Content (SEC): 260/280 Ratio		Control	1.33	1.32	1.34
		Test	1.33	1.32	1.33
<i>in vitro</i> FVIII Activity/ Functional Bioassay (% Relative Potency)		Control	72	58	62
		Test	63	58	62

Example 11: Drug Product Stability Data – 24 Months

[0147] The purpose of this study was to establish long term (24 months) stability of the SB-525 drug product at the intended storage temperature (-70°C). For this study, the SB-525 drug product (DP) was purified from Sf9 insect cells and formulated at a target of 1.00E+13 vector vg/mL in 8.10 mM Na₂HPO₄, 1.47 mM KH₂PO₄, 0.49 mM MgCl₂, 2.68 mM KCl, 172 mM NaCl, 1% (w/v) sucrose, and 0.05% (w/v) poloxamer P188, pH 7.3 ± 0.3. The DP was then filled at 6.4 mL into 10 mL Aseptic Technologies (AT) crystal closed vials, and stored at -60°C to -90°C.

[0148] Results from the DP stability study, including 5 cycles of uncontrolled F/T and 24-hour agitation, are shown in **FIG. 10**. The data show that there was no apparent trend observed in color, clarity, pH, subvisible cumulative particulate matter, capsid purity and VP ratio by R-CGE, %HMMS and UV 260/280 by SEC-HPLC, and capsid titer up to 24 months at -70°C, 12

months at 5°C, and 3 months at 25°C / 60% RH. The 12 month, 5°C sample reported “1 long fiber particle” in solution which appeared to be extrinsic in nature based on morphology and testing in uncontrolled environmental conditions (i.e., open lab space); all other samples reported “essentially free of visible particles.” No change in these quality attributes were observed after five cycles of uncontrolled F/T or 24-hour agitation.

[0149] For all the time points and conditions tested, the variability in the results for genome titer and infectious virus titer as well as infectivity ratio were within expected assay variability and did not demonstrate an apparent trend. The results for *in vitro* relative potency, a sensitive and precise stability-indicating method, show a slight downward trend in potency at the intended storage condition (-70°C) after 24 months, but the results are within the clinical stability acceptance criterion. A stability-indicating downward trend in potency at 3 months at 25°C / 60% RH and at 12 months at 5°C was also observed.

[0150] Additionally, Container Closure Integrity (CCIT) was tested at 18 months at the intended storage condition (-70°C) by a validated headspace analyzer and recorded a passing result. Six contingency vials were used for this analysis. P188 concentration was also stable for up to 18 months at -70°C, 12 months at 5°C, and 3 months at 25°C / 60% RH. A slight decrease in P188 concentration was observed at 24 months at -70°C.

CLAIMS

1. A pharmaceutical composition comprising
a recombinant adeno-associated virus (rAAV) vector,
sodium chloride (NaCl)
potassium chloride (KCl),
disodium phosphate (Na_2HPO_4),
monopotassium phosphate (KH_2PO_4),
magnesium chloride (MgCl_2),
a polyol, and
a poloxamer,
optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and
has a pH of about 7.1 to about 7.5.
2. The composition of claim 1, wherein the polyol is sucrose.
3. The composition of claim 1 or 2, wherein the poloxamer is poloxamer 188.
4. The composition of any one of claims 1-3, wherein the composition contains about 0.1 to
about 2.0 mM magnesium chloride.
5. The composition of claim 4, wherein the composition contains about 0.5 mM or higher
magnesium chloride.
6. The composition of claim 4, wherein the composition contains about 1.4 mM magnesium
chloride.
7. The composition of claim 4, wherein the composition contains more than about 1.3 mM
magnesium chloride.

8. The composition of any one of claims 1-7, wherein the composition contains about 150 to about 200 mM, optionally about 172 mM, sodium chloride.
9. The composition of any one of claims 1-8, wherein the composition contains about 2.5 to about 3.0 mM, optionally about 2.7 mM, potassium chloride.
10. The composition of any one of claims 1-9, wherein the composition contains about 5 to about 10 mM, optionally about 8 mM, disodium phosphate.
11. The composition of any one of claims 1-10, wherein the composition contains about 1.0 to about 2.0 mM, optionally about 1.5 mM, monopotassium phosphate.
12. The composition of any one of claims 1-11, wherein the composition contains about 0.5% to about 2% (w/v), optionally about 1% (w/v), sucrose.
13. The composition of any one of claims 1-12, wherein the composition contains about 0.01% to about 0.1% (w/v), optionally about 0.05% (w/v), poloxamer 188.
14. A pharmaceutical composition comprising
 - a recombinant adeno-associated virus (rAAV) vector,
 - about 171.81 mM sodium chloride,
 - about 2.68 mM potassium chloride,
 - about 8.10 mM disodium phosphate,
 - about 1.47 mM monopotassium phosphate,
 - about 1.40 mM magnesium chloride,
 - about 1.00% (w/v) sucrose, and
 - about 0.05% (w/v) poloxamer 188,optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and has a pH of about 7.1 to about 7.5.
15. A pharmaceutical composition comprising

a recombinant adeno-associated virus (rAAV) vector,
about 172 mM sodium chloride,
about 2.68 mM potassium chloride,
about 8.10 mM disodium phosphate,
about 1.47 mM monopotassium phosphate,
about 0.49 mM magnesium chloride,
about 1.00% (w/v) sucrose, and
about 0.05% (w/v) poloxamer 188,
optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and
has a pH of about 7.1 to about 7.5.

16. The composition of any one of claims 1-15, wherein the rAAV comprises a genome comprising an expression cassette for a therapeutic protein.

17. The composition of claim 16, wherein the therapeutic protein is a human factor VIII polypeptide.

18. A pharmaceutical composition comprising:

a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV comprises a genome comprising an expression cassette for expressing a human factor VIII polypeptide,

about 171.81 mM sodium chloride,
about 2.68 mM potassium chloride,
about 8.10 mM disodium phosphate,
about 1.47 mM monopotassium phosphate,
about 1.40 mM magnesium chloride,
about 1.00% (w/v) sucrose, and
about 0.05% (w/v) poloxamer 188,

optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and
has a pH of about 7.1 to about 7.5.

19. A pharmaceutical composition comprising:

a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV comprises a genome comprising an expression cassette for expressing a human factor VIII polypeptide

about 172 mM sodium chloride,
about 2.68 mM potassium chloride,
about 8.10 mM disodium phosphate,
about 1.47 mM monopotassium phosphate,
about 0.49 mM magnesium chloride,
about 1.00% (w/v) sucrose, and
about 0.05% (w/v) poloxamer 188,

optionally wherein the composition comprises no more than about 0.1 mM calcium chloride and has a pH of about 7.1 to about 7.5.

20. The composition of any one of claims 17-19, wherein the human factor VIII polypeptide comprises SEQ ID NO:1.

21. The composition of any one of claims 17-19, wherein the genome of the rAAV comprises SEQ ID NO:2 or nucleotides 131-5,024 of SEQ ID NO:2.

22. The composition of any one of claims 1-21, the composition contains the rAAV at about $1.0\text{E}+12$ to about $1.0\text{E}+14$ vector genomes (vg) per mL, optionally about $1.0\text{E}+13$ to about $5.0\text{E}+13$ vg per mL.

23. The composition of claim 22, wherein the composition contains about $1.0\text{E}+13$ vg per mL.

24. The composition of any one of the preceding claims, wherein the rAAV comprises an AAV6 capsid protein, optionally inverted terminal repeats (ITRs) of AAV2.

25. A vial comprising 5-10 mL, optionally 6.4 mL, of the composition of any one of claims 1-24.

26. The vial of claim 25, wherein the vial is made of cyclo-olefin copolymer.
27. The vial of claim 25 or 26, wherein the vial has an in-place thermoplastic elastomer stopper.
28. A method of treating a patient in need of a therapeutic protein, comprising administering to the patient the composition of any one of claims 1-24.
29. A method of increasing the serum level of factor VIII in a human subject in need thereof, comprising administering intravenously to the human subject the pharmaceutical composition of any one of claims 17-24, or the entire content of the vial of any one of claims 25-27.
30. The method of claim 29, wherein the human subject has hemophilia A.
31. A method of treating hemophilia A in a human subject in need thereof, comprising administering intravenously to the human subject the pharmaceutical composition of any one of claims 17-24, or the entire content of the vial of any one of claims 25-27.
32. Use of the pharmaceutical composition of any one of claims 1-24 for the manufacture of a medicament for treating a human subject in a method of any one of claims 28-31.
33. The pharmaceutical composition of any one of claims 1-24 for use in treating a human subject in a method of any one of claims 28-31.




Analysis	Sample	Result	Description
Digital imaging	F0		White particulate matter can be observed
Digital Imaging	F0 5x F/T		Large amounts of white particle matter can be observed
Digital Imaging	F0 after 1M at 25 °C		Large amounts of white particle matter can be observed

FIG. 1A


Polarized Light Microscopy	F0 after 1M at 25 °C	 Plane polarized  Crossed Polars	No birefringence seen under crossed-polars suggesting the material is either isotropic or amorphous
----------------------------------	----------------------	---	---

FIG. 1B



SEM/EDS	F0 5x F/T	<table><tr><th></th><th>O</th><th>P</th><th>Ca</th></tr><tr><td>Background square</td><td>28.94</td><td>32.76</td><td>0.00</td></tr><tr><td>Sample square 1</td><td>41.58</td><td>22.65</td><td>27.87</td></tr><tr><td>Sample square 2</td><td>41.55</td><td>21.14</td><td>24.13</td></tr></table>		O	P	Ca	Background square	28.94	32.76	0.00	Sample square 1	41.58	22.65	27.87	Sample square 2	41.55	21.14	24.13	There are large proportions of O, Ca and P in the sample
	O	P	Ca																
Background square	28.94	32.76	0.00																
Sample square 1	41.58	22.65	27.87																
Sample square 2	41.55	21.14	24.13																

FIG. 1C




FTIR	F0		FTIR suggest material is a salt from database search. F0, F0 5x F/T, and F0 1 M at 25°C samples all show similar spectra.
FTIR	F0 5x F/T		FTIR suggest material is a salt from database search. F0, F0 5x F/T, and F0 1 M at 25°C samples all show similar spectra.
FTIR	F0 after 1M at 25°C		FTIR suggest material is a salt from database search. F0, F0 5x F/T, and F0 1 M at 25°C samples all show similar spectra.

FIG. 1D



Digital Imaging	F0 5x F/T (lot 2)		White particle matter observed
FTIR	F0 5x F/T (lot 2)		Resembles spectra for F0 from previous lot
Raman microscopy	F0 5x F/T		Material identified as calcium phosphate

FIG. 1F




FIG. 2




FIG. 3




FIG. 4A




FIG. 4B

Formulation	Condition	Appearance	pH	Monomer Peak Mean Size (nm)	Polydisp. Index	% Monomer DLS	% HMWS, DLS	% HMWS, SE-LC	% Full Capsids
F0	Initial	Pass	7.3	29.7	0.07	100.0%	0%	0.2%	89.2%
	3x F/T	Pass	7.3	30.7	0.12	99.6%	0.4%	ND	ND
	5x F/T	Fail	7.3	30.4	0.08	100.0%	0%	ND	ND
	10x F/T	Fail	7.3	30.2	0.07	100.0%	0%	0.0%	89.3%
F1	Initial	Pass	7.3	33.0	0.12	100.0%	0%	0.5%	89.1%
	3x F/T	Pass	7.2	32.8	0.13	100.0%	0%	ND	ND
	5x F/T	Pass	7.2	34.3	0.13	100.0%	0%	ND	ND
	10x F/T	Pass	7.3	33.4	0.12	100.0%	0%	0.6 %	89.2%
F2	Initial	Pass	7.2	33.6	0.14	100.0%	0%	0.5%	89.3%
	3x F/T	Pass	7.2	34.0	0.14	100.0%	0%	ND	ND
	5x F/T	Pass	7.3	33.9	0.13	100.0%	0%	ND	ND
	10x F/T	Pass	7.2	33.6	0.13	100.0%	0%	0.5%	89.3%
F3	Initial	Pass	7.2	33.4	0.12	100.0%	0%	0.4%	89.1%
	3x F/T	Pass	7.2	33.3	0.12	100.0%	0%	ND	ND
	5x F/T	Pass	7.2	33.6	0.13	100.0%	0%	ND	ND
	10x F/T	Pass	7.3	33.7	0.13	100.0%	0%	0.3%	89.0%

ND: No data.

FIG. 4C

Formulation	Condition	VG Titer (vg/mL)	Infectious Titer (TCID ₅₀ /mL)	VG/TCID ₅₀	Capsid Titer (capsids/mL)	Monomer Conc, SE-LC (p/mL)	Monomer Conc, MADLS (p/mL)
F0	Initial	7.9E+12	9.3E+09	1200	5.0E+12	1.0E+13	7.8E+12
	3x F/T	ND	ND	ND	ND	ND	8.3E+12
	5x F/T	9.5E+12	ND	ND	ND	ND	8.3E+12
	10x F/T	9.9E+12	9.3E+09	700	6.2E+12	8.6E+12	7.8E+12
F1	Initial	8.3E+12	9.3E+09	1100	5.5E+12	9.5E+12	6.4E+12
	3x F/T	ND	ND	ND	ND	ND	6.7E+12
	5x F/T	1.1E +13	ND	ND	NO	ND	7.0E+12
	10x F/T	1.1E+13	2.9E+10	300	5.7E+12	9.5E+12	5.9E+12
F2	Initial	9.4E+12	1.1E+10	1100	5.2E+12	9.9E+12	7.3E+12
	3x F/T	ND	ND	ND	ND	ND	6.8E+12
	5x F/T	1.2E+13	ND	ND	ND	ND	1.0E+13
	10x F/T	1.2E+13	2.4E+10	400	5.6E+12	1.0E+13	6.4E+12
F3	Initial	7.7E+12	1.1E+09	8400	6.7E+12	9.7E+12	8.2E+12
	3x F/T	ND	ND	ND	ND	ND	6.1E+12
	5x F/T	1.8E+13	ND	ND	ND	ND	6.0E+12
	10x F/T	1.3E+13	3.6E+09	2600	5.7E+12	1.0E+13	5.7E+12

FIG. 4D




FIG. 5A




FIG. 5B

Formulation	Condition	Appearance	pH	Monomer Peak Mean Size (nm)	Polydisp. Index	% Monomer, DLS	% HMWS, DLS	% HMWS, SE-LC	% Full Capsids
F0	Initial	Pass	7.3	29.7	0.07	100.0%	0.0%	0.2%	89.2%
	1 week	Pass	7.3	ND	ND	ND	ND	ND	ND
	1 month	Pass	7.3	30.2	0.08	100.0%	0.0%	ND	ND
	2 months	Pass	7.2	30.1	0.07	100.0%	0.0%	0.7%	NAA
	3 months	Pass	7.4	32.9	0.13	100.0%	0.0%	0.0%	NAA
	6 months	Pass	7.2	30.6	0.08	100.0%	0.0%	ND	ND
F1	Initial	Pass	7.3	33.0	0.12	100.0%	0.0%	0.5%	89.1%
	1 week	Pass	7.1	ND	ND	ND	ND	ND	ND
	1 month	Pass	7.2	34.3	0.14	100.0%	0.0%	ND	ND
	2 months	Pass	7.2	34.4	0.14	100.0%	0.0%	1.9%	NAA
	3 months	Pass	7.2	36.4	0.17	99.6%	0.4%	5.5%	NAA
	6 months	Pass	7.2	ND	ND	ND	ND	ND	ND
F2	Initial	Pass	7.2	33.6	0.14	100.0%	0.0%	0.5%	89.3%
	1 week	Pass	7.2	ND	ND	ND	ND	ND	ND
	1 month	Pass	7.2	34.2	0.13	100.0%	0.0%	ND	ND
	2 months	Pass	7.2	34.6	0.14	100.0%	0.0%	0.8%	NAA
	3 months	Pass	7.2	35.4	0.17	99.5%	0.5%	1.3%	NAA
	6 months	Pass	7.3	34.0	0.13	100.0%	0.0%	ND	ND
F3	Initial	Pass	7.2	33.4	0.12	100.0%	0.0%	0.4%	89.1%
	1 week	Pass	7.2	ND	ND	ND	ND	ND	ND
	1 month	Pass	7.3	33.6	0.13	100.0%	0.0%	ND	ND
	2 months	Pass	7.2	33.5	0.12	100.0%	0.0%	0.6%	NAA
	3 months	Pass	7.4	34.7	0.17	99.2%	0.8%	1.7%	NAA
	6 months	Pass	7.2	33.9	0.13	100.0%	0.0%	ND	ND

FIG. 5C

Formulation	Condition	VG Titer (vg/mL)	Infectious Titer (TCID ₅₀ /mL)	VG/TCID ₅₀	Capsid Titer (capsids/mL)	Monomer Conc, SE-LC (p/mL)	Monomer Conc, MADLS (p/mL)
F0	Initial	7.9E+12	9.3E+09	1200	5.0E+12	1.0E+13	7.8E+12
	1 month	6.6E+12	ND	ND	ND	ND	8.6E+12
	2 months	4.9E+12	ND	ND	5.5E+12	9.0E+12	8.4E+12
	3 months	9.2E+12	2.4E+09	1100	5.3E+12	8.4E+12	8.6E+12
	6 months	ND	2.0E+09	ND	ND	ND	7.7E+12
F1	Initial	8.3E+12	9.3E+09	1100	5.5E+12	9.5E+12	6.4E+12
	1 month	4.5E+12	ND	ND	ND	ND	1.2E+13
	2 months	4.8E+12	ND	ND	5.3E+12	8.6E+12	1.5E+13
	3 months	1.1E+13	2.9E+09	600	6.3E+12	8.7E+12	4.8E+12
	6 months	ND	5.2E+08	ND	ND	ND	ND
F2	Initial	9.4E+12	1.1E+10	1100	5.2E+12	9.9E+12	7.3E+12
	1 month	3.9E+12	ND	ND	ND	ND	6.7E+12
	2 months	5.9E+12	ND	ND	5.5E+12	9.3E+12	7.6E+12
	3 months	8.2E+12	3.6E+09	1300	6.0E+12	1.1E+13	8.6E+12
	6 months	ND	2.4E+09	ND	ND	ND	6.5E+12
F3	Initial	7.7E+12	1.1 E+09	8400	6.7E+12	9.7E+12	8.2E+12
	1 month	4.8E+12	ND	ND	ND	ND	6.5E+12
	2 months	5.6E+12	ND	ND	5.3E+12	1.0E+13	7.1E +12
	3 months	9.5E+12	6.3E+09	500	6.8E+12	9.5E+12	7.3E+12
	6 months	ND	2.0E+09	ND	ND	ND	7.5E+12

FIG. 5D




FIG. 6A




FIG. 6B

FIG. 6C

Formulation	Condition	Appearance	pH	Monomer Peak Mean Size (nm)	Polydisp. Index	% Monomer, DLS	% HMWS, DLS	% HMWS, SE-LC	% Full Capsids
F0	Initial	Pass	7.3	29.7	0.07	100.0%	0.0%	0.2%	89.2%
	3 days	Pass	7.3	34.1	0.15	99.6 %	0.4%	ND	ND
	1 week	Pass	7.4	35.0	0.14	100.0%	0.0%	ND	ND
	2 weeks	Pass	7.3	35.9	0.20	98.1%	1.9%	ND	ND
	1 month	Pass	7.3	33.4	0.14	100.0%	0.0%	5.4%	NAA
	2 months	Pass	7.1	28.8	0.36	94.6%	5.4%	0.0%	NAA
	3 months	Fail	7.1	32.6	0.32	87.6%	12.4%	0.0%	NAA
	7 months	ND	ND	32.8	0.50	72.7%	27.3%	ND	ND
F1	Initial	Pass	7.3	33.0	0.12	100.0 %	0.0%	0.5%	89.1%
	3 days	Pass	7.2	ND	ND	ND	ND	ND	ND
	1 week	Pass	7.2	ND	ND	ND	ND	ND	ND
	2 weeks	Pass	7.2	ND	ND	ND	ND	ND	ND
	1 month	Pass	7.2	43.9	0.25	96.5%	3.6%	15.2%	NAA
	2 months	Pass	7.2	40.6	0.22	98.5%	1.5%	4.5%	NAA
	3 months	Fail	7.2	41.7	0.24	96.9%	3.1%	20.3%	NAA
	7 months	ND	ND	46.7	0.24	99.0%	1.0%	ND	ND
F2	Initial	Pass	7.2	33.6	0.14	100.0%	0.0%	0.5%	89.3%
	3 days	Pass	7.2	39.5	0.22	96.6%	3.4%	ND	ND
	1 week	Pass	7.2	45.1	0.25	94.5%	5.5%	ND	ND
	2 weeks	Pass	7.2	42.2	0.26	92.6%	7.4%	ND	ND
	1 month	Pass	7.2	41.3	0.23	97.6%	2.4%	6.5%	NAA
	2 months	Pass	7.2	42.0	0.23	98.5%	1.5%	11.6%	NAA
	3 months	Fail	7.3	40.3	0.24	95.0%	5.0%	17.1%	NAA
	7 months	ND	ND	55.4	0.28	97.5%	2.5%	ND	ND
F3	Initial	Pass	7.2	33.4	0.12	100.0%	0.0%	0.4%	89.1%
	3 days	Pass	7.2	36.3	0.23	96.6%	3.4%	ND	ND
	1 week	Pass	7.2	40.2	0.20	98.4%	1.6%	ND	ND
	2 weeks	Pass	7.2	42.9	0.22	98.2%	1.8%	ND	ND
	1 month	Pass	7.2	37.7	0.18	100.0%	0.0%	3.5%	NAA
	2 months	Pass	7.2	37.9	0.20	98.9%	1.1%	5.6%	NAA

Formulation	Condition	Appearance	pH	Monomer Peak Mean Size (nm)	Polydisp. Index	% Monomer, DLS	% HMWS, DLS	% HMWS, SE-LC	% Full Capsids
	3 months	Fail	7.3	39.2	0.25	92.8%	7.2%	9.5%	NAA
	7 months	ND	ND	46.9	0.36	82.4%	17.6%	ND	ND

FIG. 6C (cont'd)

FIG. 6D

Formulation	Condition	VG Titer (vg/mL)	Infectious Titer (TCID ₅₀ /mL)	VG/TCID ₅₀	Capsid Titer (capsids/mL)	Monomer Conc. SE-LC, (p/mL)	Monomer Conc. (MADLS (p/mL)
F0	Initial	7.9E+12	9.3E+09	1200	5.0E+12	1.0E+13	7.8 E+12
	3 days	ND	ND	ND	ND	ND	6.3E+12
	1 week	ND	ND	ND	ND	ND	5.4E+12
	2 weeks	ND	ND	ND	ND	ND	3.2E+12
	1 month	8.1E+12	1.7E+07	440000	4.5E+12	5.9E+12	4.0 E+12
	2 months	4.5E+12	ND	ND	3.2E+12	3.9E+12	5.1E+13
	3 months	ND	ND	ND	3.6E+12	4.4E+12	5.2E+12
F1	7 months	ND	ND	ND	ND	ND	1.2E+13
	Initial	8.3E+12	9.3E+09	1100	2.6E+12	9.5E+12	6.4E+12
	3 days	ND	ND	ND	ND	ND	ND
	1 week	ND	ND	ND	ND	ND	ND
	2 weeks	ND	ND	ND	ND	ND	ND
	1 month	3.8E+12	1.1E+07	280000	2.6E+12	4.2E+12	1.0E+13
	2 months	5.7E+12	ND	ND	2.5E+12	4.2E+12	8.6E+12
F2	3 months	ND	ND	ND	2.4E+12	6.6E+12	1.8E+13
	7 months	ND	ND	ND	ND	ND	1.0E+14
	Initial	9.4E+12	1.1E+10	1100	5.2E+12	9.9E+12	7.3E+12
	3 days	ND	ND	ND	ND	ND	9.2E+12
	1 week	ND	ND	ND	ND	ND	1.5E+13
	2 weeks	ND	ND	ND	ND	ND	1.5E+13
	1 month	7.8E+12	1.4E+07	410000	3.4E+12	4.9E+12	1.4E+13
F3	2 months	6.0E+12	ND	ND	2.9E+12	5.9E+12	2.2E+13
	3 months	ND	ND	ND	3.4E+12	9.0E+12	3.2E+13
	7 months	ND	ND	ND	ND	ND	1.0E+13
	Initial	7.7E+12	1.1E+09	8400	6.7E+12	9.7E+12	8.2E+12
	3 days	ND	ND	ND	ND	ND	6.8E+12
	1 week	ND	ND	ND	ND	ND	2.8E+13
	2 weeks	ND	ND	ND	ND	ND	1.5E+13
	1 month	8.7E+12	2.0E+08	42000	4.9E+12	6.2E+12	5.5E+12
	2 months	9.3E+12	ND	ND	2.7E+12	7.2E+12	8.0E+12

Formulation	Condition	VG Titer (vg/mL)	Infectious Titer (TCID ₅₀ /mL)	VG/TCID ₅₀	Capsid Titer (capsids/mL)	Monomer Conc. SE-LC, (p/mL)	Monomer Conc. (MADLS (p/mL)
	3 months	ND	ND	ND	2.8E+12	9.4E+12	1.3E+13
	7 months	ND	ND	ND	ND	ND	1.1E+13

FIG. 6D (cont'd)

Quality Attribute	Testing Method	Method Variability	Stability Acceptance Criteria	Failure Criteria
Appearance Liquid	Visual inspection	N/A	Clear colorless, free of particulates	Hazy, cloudy, or visual detection of particles
pH	Potentiometric	± 0.1	7.1 - 7.5	< 7.1 or > 7.5
Monomer Peak Mean Size	DLS	< 10%	< 10% change from initial (t ₀)	> +25% change from initial
Polydispersity Index	DLS	< 10%	PDI < 0.20	PDI > 0.25
Monomer Fraction	DLS	< 2.5%	> 97.5% monomer	< 95% monomer
HMWS Fraction	DLS	< 2.5%	< 2.5% HMWS	> 5% HMWS
HMWS Fraction	SE-LC	< 10%	< 5% HMWS	> 10% HMWS
% Full Capsids	AEX-LC	< 10%	> 85% full capsids	< 80% full capsids
Vector Genome Titer	qPCR	36.0%	-36% to +36% change from initial	< -50% change from initial
Infectious Titer	TCID ₅₀	50.0%	-50% to +50% change from initial	< -60% change from initial
VG/TCID ₅₀ Ratio	Calculation	86.0%	-0.5 to +0.5 -log ₁₀ change from initial	< -1 -log ₁₀ change from initial
Capsid Concentration	ELISA	20.0%	-20% to +20% change from initial	< -40% change from initial
Monomer Concentration	SE-LC	30.0%	-30% to +30% change from initial	< -40% change from initial
Monomer Concentration	MADLS	< 30%	-25% to +25% change from initial	< -40% change from initial

FIG. 7

	Test	Appearance, Liquid	pH	Monomer Peak Mean Size	Polydisp Index	Monomer Fraction, DLS	HMWS Fraction, DLS	HMWS Fraction, SE- LC	% Full Capsids, AEX-LC
Form	Condition	Pass/Fail	pH	% change from <i>t</i> ₀	PDI	% Monomer	% HMWS	% HMWS	% Full
F0	Initial	Pass	7.3	29.65	0.07	100.0%	0.0%	0.2%	89.2%
	10x F/T	Fail	7.3	1.8%	0.07	99.6%	0.4%	0.0%	89.3%
	3 mo 25°C / 60%RH	Pass	7.4	11.1%	0.13	99.6%	0.4%	0.0%	NAA
	1 mo 40°C / 75%RH	Pass	7.3	12.6%	0.14	100.0%	0.0%	5.4%	NAA
	Assessment	Fail	Pass	Neutral	Neutral	Pass	Pass	Neutral	Pass
F1	Initial	Pass	7.3	33.0	0.12	100.0%	0.0%	0.5%	89.1%
	10x F/T	Pass	7.3	1.0%	0.12	100.0%	0.0%	0.6%	89.2%
	3 mo 25°C / 60%RH	Pass	7.2	10.3%	0.17	100.0%	0.0%	5.5%	NAA
	1 mo 40°C / 75%RH	Pass	7.2	32.9%	0.25	85.5%	14.5%	15.2%	NAA
	Assessment	Pass	Pass	Fail	Fail	Fail	Fail	Fail	Pass
F2	Initial	Pass	7.2	33.6	0.14	100.0%	0.0%	0.5%	89.3%
	10x F/T	Pass	7.2	0.0%	0.13	100.0%	0.0%	0.5%	89.3%
	3 mo 25°C / 60%RH	Pass	7.2	5.4%	0.17	98.4%	1.6%	1.3%	NAA
	1 mo 40°C / 75%RH	Pass	7.2	23.0%	0.23	99.7%	0.4%	6.5%	NAA
	Assessment	Pass	Pass	Neutral	Neutral	Pass	Pass	Neutral	Pass
F3	Initial	Pass	7.2	33.4	0.12	100.0%	0.0%	0.4%	89.1%
	10x F/T	Pass	7.3	1.0%	0.13	99.5%	0.5%	0.3%	89.0%
	3 mo 25°C / 60%RH	Pass	7.4	3.8%	0.17	100.0%	0.0%	1.7%	NAA
	1 mo 40°C / 75%RH	Pass	7.2	12.9%	0.18	100.0%	0.0%	3.5%	NAA
	Assessment	Pass	Pass	Neutral	Neutral	Pass	Pass	Pass	Pass

FIG. 8

Test		VG Titer, qPCR	Infect Titer, TCID ₅₀	VG / TCID ₅₀ Ratio	Capsid Conc, ELISA	Monomer Conc, SE-LC	Monomer Conc, MADLS
Form	Condition	% change from t0	% change from t0	Neg. log change from t0	% change from t0	% change from t0	% change from t0
F0	Initial	7.9E+12	9.3E+09	1200	5.0E+12	1.0E+13	7.8E+12
	10x F/T	25.1%	0.0%	0.23	24.5%	-13.3%	10.8%
	3 mo 25°C / 60%RH	16.9%	-73.9%	0.02	6.6%	-14.8%	32.0%
	1 mo 40°C / 75%RH	3.2%	-99.8%	-2.57	-9.6%	-40.7%	-43.3%*
	Assessment	Pass	No Score	No Score	Pass	Neutral	Neutral
F1	Initial	8.3E+12	9.3E+09	1100	5.5E+12	9.5E+12	6.4E+12
	10x F/T	36.5%	216.2%	0.54	4.2%	0.2%	-5.5%
	3 mo 25°C / 60%RH	31.4%	-68.3%	0.26	13.6%	-8.5%	-4.6%
	1 mo 40°C / 75%RH	-54.5%	-99.9%	-2.39	-52.1%	-55.5%	28.9%*
	Assessment	Fail	No Score	No Score	Neutral	Neutral	Neutral
F2	Initial	9.4E+12	1.1E+10	1100	5.2E+12	9.9E+12	7.3E+12
	10x F/T	27.3%	115.4%	0.46	7.7%	5.1%	-17.5%
	3 mo 25°C / 60%RH	-13.2%	-68.4%	-0.05	15.8%	6.8%	11.4%
	1 mo 40°C / 75%RH	-17.6%	-99.9%	-2.56	-34.4%	-50.7%	65.9%*
	Assessment	Pass	No Score	No Score	Pass	Neutral	Neutral
F3	Initial	7.7E+12	1.1E+09	8400	6.7E+12	9.7E+12	7.7E+12
	10x F/T	68.9%	216.2%	0.5	-15.2%	3.7%	-23.6%
	3 mo 25°C / 60%RH	22.8%	462.3%	1.27	2.6%	-1.5%	-15.0%
	1 mo 40°C / 75%RH	12.6%	-82.2%	-0.7	-27.0%	-36.1%	0.1%*
	Assessment	Neutral	No Score	No Score	Pass	Pass	Pass

* Result was not reproducible and not considered for final scoring

FIG. 9

Stability Results

Test		Temp (°C)	T0	1 month	3 months	6 months	9 months	12 months	18 months	24 months
Appearance, Liquid	Color	-70	Clear	≤B9	≤B9	≤B9	≤B9	≤B9	≤B9	≤B9
		5		≤B9	≤B9					
		25		≤B9	≤B9					
	Clarity	-70	Colorless	≤Ref I	≤Ref I	≤Ref I	≤Ref I	≤Ref I	≤Ref I	≤Ref I
		5		≤Ref I	≤Ref I					
		25		≤Ref I	≤Ref I					
	Visible Particles	-70	No visible particulates	EFVP	EFVP	EFVP	EFVP	EFVP	EFVP	EFVP
		5		EFVP	EFVP		1-5 prtcl*			
		25		EFVP						
Container Closure Integrity		-70							Pass	
pH		-70	7.4	7.5	7.4	7.4	7.4	7.4	7.3	7.3
		5		7.4	7.3	7.3		7.4		
		25		7.4	7.3					
Genome Titer (qPCR)		-70	1.06E+13	8.12E+12	9.17E+12	7.45E+12	1.14E+13	8.77E+12	9.05E+12	7.41E+12
		5		7.69E+12	8.93E+12	6.79E+12		9.00E+12		
		25		7.93E+12	9.26E+12					
Capsid Titer (ELISA)		-70	1.50E+13	1.05E+13	1.28E+13	1.07E+13	1.21E+13	1.40E+13	1.59E+13	1.07E+13
		5		1.14E+13	1.26E+13	1.14E+13		1.26E+13		
		25		1.06E+13	1.23E+13					
Infectious Titer (TCID ₅₀)		-70	4.31E+09	2.93E+09	2.20E+09	9.29E+08	3.56E+09	1.82E+09	2.00E+09	7.67E+09
		5		2.00E+09	9.27E+08	1.36E+09		5.22E+09		
		25		5.22E+09	1.12E+09					
Genome Titer / Infectious Titer Ratio		-70	2459	3618	4818	11410	2978	5824	5300	1382
Capsid Protein Purity (CE): % Capsid		-70	94.8	94.4	94.5	94.5	94.7	94.6	94.5	94.9
		5		94.2	94.8	94.5		94.8		
		25		94.3	93.5					
Capsid Protein Purity (CE): % Other		-70	NR	5.6	5.5	5.5	5.3	5.4	5.5	5.1
		5		5.8	5.2	5.5		5.2		
		25		5.7	6.5					

FIG. 10

Test	Temp (°C)	T0	1 month	3 months	6 months	9 months	12 months	18 months	24 months
Size Distribution (SEC): % Monomer	-70	99.4	98.9	98.9	99.2	99.0	99.3	99.2	99.0
	5		99.1	98.8	99.3		99.1		
	25		98.5	98.5					
Size Distribution (SEC): % Aggregates	-70	NMT 1.0	1.1	1.1	NMT 1.0	1.0	N/A	NMT 1.0	NMT 1.0
	5		NMT 1.0	1.2	NMT 1.0		NMT 1.0		
	25		1.5	1.5					
Particle Content (SEC): 260/280 Ratio	-70	1.32	1.32	1.32	1.32	1.32	1.32	1.33	1.32
	5		1.32	1.32	1.32		1.32		
	25		1.32	1.33					
In vitro FVIII Activity/ Functional Bioassay (% Relative Potency)	-70	73	76	82	64	60	69	60	55
	5		73	60	60		48		
	25		61	42					
P188 Concentration	-70	NT	443.8	454.4	456.8	432.3	464.2	504.8	399.0
	5		NT	467.2	455.7		466.6		
	25		454.7	461.9					

* 1-5 particles (prtcl); particle description – “1 long fiber particle”
NR: Not reported, NTM: Not more than, NT: not tested

FIG. 10 (cont'd)

SEQUENCE LISTING

<110> SANGAMO THERAPEUTICS, INC.
PFIZER INC.

<120> IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED
VIRAL VECTOR

<130> 025297.W0029

<140>

<141>

<150> 63/127,826

<151> 2020-12-18

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 1457

<212> PRT

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polypeptide"

<400> 1

Met	Gln	Ile	Glu	Leu	Ser	Thr	Cys	Phe	Phe	Leu	Cys	Leu	Leu	Arg	Phe
1				5				10						15	

Cys	Phe	Ser	Ala	Thr	Arg	Arg	Tyr	Tyr	Leu	Gly	Ala	Val	Glu	Leu	Ser
			20				25						30		

Trp	Asp	Tyr	Met	Gln	Ser	Asp	Leu	Gly	Glu	Leu	Pro	Val	Asp	Ala	Arg
		35					40					45			

Phe	Pro	Pro	Arg	Val	Pro	Lys	Ser	Phe	Pro	Phe	Asn	Thr	Ser	Val	Val
		50				55					60				

Tyr	Lys	Lys	Thr	Leu	Phe	Val	Glu	Phe	Thr	Asp	His	Leu	Phe	Asn	Ile
65				70					75					80	

Ala	Lys	Pro	Arg	Pro	Pro	Trp	Met	Gly	Leu	Leu	Gly	Pro	Thr	Ile	Gln
				85					90					95	

Ala Glu Val Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser
100 105 110

His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser
115 120 125

Glu Gly Ala Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp
130 135 140

Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu
145 150 155 160

Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr Ser
165 170 175

Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile
180 185 190

Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr
195 200 205

Gln Thr Leu His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly
210 215 220

Lys Ser Trp His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp
225 230 235 240

Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr
245 250 255

Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val
260 265 270

Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile
275 280 285

Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala Ser
290 295 300

Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met

305		310		315		320									
Asp	Leu	Gly	Gln	Phe	Leu	Leu	Phe	Cys	His	Ile	Ser	Ser	His	Gln	His
			325						330					335	
Asp	Gly	Met	Glu	Ala	Tyr	Val	Lys	Val	Asp	Ser	Cys	Pro	Glu	Glu	Pro
			340					345					350		
Gln	Leu	Arg	Met	Lys	Asn	Asn	Glu	Glu	Ala	Glu	Asp	Tyr	Asp	Asp	Asp
		355					360					365			
Leu	Thr	Asp	Ser	Glu	Met	Asp	Val	Val	Arg	Phe	Asp	Asp	Asp	Asn	Ser
	370					375					380				
Pro	Ser	Phe	Ile	Gln	Ile	Arg	Ser	Val	Ala	Lys	Lys	His	Pro	Lys	Thr
385					390					395					400
Trp	Val	His	Tyr	Ile	Ala	Ala	Glu	Glu	Glu	Asp	Trp	Asp	Tyr	Ala	Pro
				405					410					415	
Leu	Val	Leu	Ala	Pro	Asp	Asp	Arg	Ser	Tyr	Lys	Ser	Gln	Tyr	Leu	Asn
			420					425					430		
Asn	Gly	Pro	Gln	Arg	Ile	Gly	Arg	Lys	Tyr	Lys	Lys	Val	Arg	Phe	Met
		435					440					445			
Ala	Tyr	Thr	Asp	Glu	Thr	Phe	Lys	Thr	Arg	Glu	Ala	Ile	Gln	His	Glu
	450					455					460				
Ser	Gly	Ile	Leu	Gly	Pro	Leu	Leu	Tyr	Gly	Glu	Val	Gly	Asp	Thr	Leu
465					470					475					480
Leu	Ile	Ile	Phe	Lys	Asn	Gln	Ala	Ser	Arg	Pro	Tyr	Asn	Ile	Tyr	Pro
				485					490					495	
His	Gly	Ile	Thr	Asp	Val	Arg	Pro	Leu	Tyr	Ser	Arg	Arg	Leu	Pro	Lys
			500					505					510		
Gly	Val	Lys	His	Leu	Lys	Asp	Phe	Pro	Ile	Leu	Pro	Gly	Glu	Ile	Phe
		515					520					525			

Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp
530 535 540

Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg
545 550 555 560

Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu
565 570 575

Ser Val Asp Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val
580 585 590

Ile Leu Phe Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr Glu
595 600 605

Asn Ile Gln Arg Phe Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp
610 615 620

Pro Glu Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val
625 630 635 640

Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp
645 650 655

Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe
660 665 670

Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr
675 680 685

Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro
690 695 700

Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly
705 710 715 720

Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr Gly Asp
725 730 735

Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys

740

745

750

Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Pro Pro Val Leu
755 760 765

Lys Arg His Gln Arg Glu Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln
770 775 780

Glu Glu Ile Asp Tyr Asp Asp Thr Ile Ser Val Glu Met Lys Lys Glu
785 790 795 800

Asp Phe Asp Ile Tyr Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe
805 810 815

Gln Lys Lys Thr Arg His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp
820 825 830

Asp Tyr Gly Met Ser Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln
835 840 845

Ser Gly Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr
850 855 860

Asp Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu His
865 870 875 880

Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile
885 890 895

Met Val Thr Phe Arg Asn Gln Ala Ser Arg Pro Tyr Ser Phe Tyr Ser
900 905 910

Ser Leu Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly Ala Glu Pro Arg
915 920 925

Lys Asn Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr Phe Trp Lys Val
930 935 940

Gln His His Met Ala Pro Thr Lys Asp Glu Phe Asp Cys Lys Ala Trp
945 950 955 960

Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His Ser Gly Leu
965 970 975

Ile Gly Pro Leu Leu Val Cys His Thr Asn Thr Leu Asn Pro Ala His
980 985 990

Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu Phe Phe Thr Ile Phe
995 1000 1005

Asp Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Met Glu Arg Asn
1010 1015 1020

Cys Arg Ala Pro Cys Asn Ile Gln Met Glu Asp Pro Thr Phe Lys
1025 1030 1035

Glu Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Ile Met Asp Thr
1040 1045 1050

Leu Pro Gly Leu Val Met Ala Gln Asp Gln Arg Ile Arg Trp Tyr
1055 1060 1065

Leu Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe
1070 1075 1080

Ser Gly His Val Phe Thr Val Arg Lys Lys Glu Glu Tyr Lys Met
1085 1090 1095

Ala Leu Tyr Asn Leu Tyr Pro Gly Val Phe Glu Thr Val Glu Met
1100 1105 1110

Leu Pro Ser Lys Ala Gly Ile Trp Arg Val Glu Cys Leu Ile Gly
1115 1120 1125

Glu His Leu His Ala Gly Met Ser Thr Leu Phe Leu Val Tyr Ser
1130 1135 1140

Asn Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His Ile Arg
1145 1150 1155

Asp Phe Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro

1160

1165

1170

Lys Leu Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser
 1175 1180 1185

Thr Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu Ala Pro
 1190 1195 1200

Met Ile Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln Lys Phe
 1205 1210 1215

Ser Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr Ser Leu Asp
 1220 1225 1230

Gly Lys Lys Trp Gln Thr Tyr Arg Gly Asn Ser Thr Gly Thr Leu
 1235 1240 1245

Met Val Phe Phe Gly Asn Val Asp Ser Ser Gly Ile Lys His Asn
 1250 1255 1260

Ile Phe Asn Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu His Pro
 1265 1270 1275

Thr His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly
 1280 1285 1290

Cys Asp Leu Asn Ser Cys Ser Met Pro Leu Gly Met Glu Ser Lys
 1295 1300 1305

Ala Ile Ser Asp Ala Gln Ile Thr Ala Ser Ser Tyr Phe Thr Asn
 1310 1315 1320

Met Phe Ala Thr Trp Ser Pro Ser Lys Ala Arg Leu His Leu Gln
 1325 1330 1335

Gly Arg Ser Asn Ala Trp Arg Pro Gln Val Asn Asn Pro Lys Glu
 1340 1345 1350

Trp Leu Gln Val Asp Phe Gln Lys Thr Met Lys Val Thr Gly Val
 1355 1360 1365

Thr Thr Gln Gly Val Lys Ser Leu Leu Thr Ser Met Tyr Val Lys
1370 1375 1380

Glu Phe Leu Ile Ser Ser Ser Gln Asp Gly His Gln Trp Thr Leu
1385 1390 1395

Phe Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn Gln Asp
1400 1405 1410

Ser Phe Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu Leu Thr
1415 1420 1425

Arg Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile Ala
1430 1435 1440

Leu Arg Met Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr
1445 1450 1455

<210> 2

<211> 5132

<212> DNA

<213> Artificial Sequence

<220>

<221> source

<223> /note="Description of Artificial Sequence: Synthetic
polynucleotide"

<400> 2

ctgcgcgtc gctcgctcac tgaggccgcc cgggcaaagc ccgggcgtcg ggcgaccttt 60

ggtcgcccgg cctcagttag cgagcgagcg cgcagagagg gaggggcga ctccatcact 120

aggggttcct gcggcctaag cttggaacca ttgccacctt cagggggagg ctgctggtga 180

atattaacca agatcacccc agttaccgga ggagcaaaca gggactaagt tcacacgcgt 240

ggtaccgtct gtctgcacat ttcgtagagc gagggttccg atactcta atctcctaggc 300

aagggttcata tttgtgtagg ttacttattc tccttttggt gactaagtca ataatacaga 360

tcagcagggt tggagtcagc ttggcaggga tcagcagcct ggggttggaag gaggggggtat 420

aaaagcccct tcaccaggag aagccgtcac acagatccac aagctcctga agaggtaagg 480

gtttaagtta tcgttagttc gtgcaccatt aatgtttaat tacctggagc acctgcctga 540

aatcatTTTT ttttcaggtt ggctagtatg cagatcgagc tctccacctg cttctttctg	600
tgctgttga gattctgctt cagcgccacc aggagatact acctgggggc tgtggagctg	660
agctgggact acatgcagtc tgacctgggg gagctgcctg tggatgccag gttccccccc	720
agagtgccca agagcttccc cttcaacacc tctgtggtgt acaagaagac cctgtttgtg	780
gagttcactg accacctgtt caacattgcc aagcccaggc ccccctggat gggcctgctg	840
ggccccacca tccaggctga ggtgtatgac actgtggtga tcaccctgaa gaacatggcc	900
agccaccctg tgagcctgca tgctgtgggg gtgagctact ggaaggcctc tgagggggct	960
gagtatgatg accagaccag ccagaggag aaggaggatg acaaggtgtt ccctgggggc	1020
agccacacct atgtgtggca ggtgctgaag gagaatggcc ccatggcctc tgaccccctg	1080
tgctgacct acagctacct gagccatgtg gacctggtga aggacctgaa ctctggcctg	1140
attggggccc tgctggtgtg caggggaggc agcctggcca aggagaagac ccagaccctg	1200
cacaagttca tcctgctgtt tgctgtgttt gatgagggca agagctggca ctctgaaacc	1260
aagaacagcc tgatgcagga cagggatgct gcctctgccca gggcctggcc caagatgcac	1320
actgtgaatg gctatgtgaa caggagcctg cctggcctga ttggctgccca caggaagtct	1380
gtgtactggc atgtgattgg catgggcacc acccctgagg tgcacagcat cttcctggag	1440
ggccacacct tcctggctcag gaaccacagg caggccagcc tggagatcag ccccatcacc	1500
ttcctgactg cccagaccct gctgatggac ctggggcagt tcctgctgtt ctgccacatc	1560
agcagccacc agcatgatgg catggaggcc tatgtgaagg tggacagctg ccctgaggag	1620
ccccagctga ggatgaagaa caatgaggag gctgaggact atgatgatga cctgactgac	1680
tctgagatgg atgtggtgag gttt gatgat gacaacagcc ccagcttcat ccagatcagg	1740
tctgtggcca agaagcacc caagacctgg gtgcactaca ttgctgctga ggaggaggac	1800
tgggactatg ccccctggt gctggcccct gatgacagga gctacaagag ccagtacctg	1860
aacaatggcc cccagaggat tggcaggaag tacaagaagg tcaggttcat ggcctacact	1920
gatgaaacct tcaagaccag ggaggccatc cagcatgagt ctggcatcct gggccccctg	1980
ctgtatgggg aggtggggga caccctgctg atcatcttca agaaccaggc cagcaggccc	2040
tacaacatct acccccatgg catcactgat gtgaggcccc tgtacagcag gaggctgccc	2100
aagggggtga agcacctgaa ggacttcccc atcctgcctg gggagatctt caagtacaag	2160

tggactgtga ctgtggagga tggccccacc aagtctgacc ccaggtgcct gaccagatac	2220
tacagcagct ttgtgaacat ggagagggac ctggcctctg gcctgattgg ccccctgctg	2280
atctgctaca aggagtctgt ggaccagagg ggcaaccaga tcatgtctga caagaggaat	2340
gtgatcctgt tctctgtggt tgatgagaac aggagctggg acctgactga gaacatccag	2400
aggttcctgc ccaaccctgc tggggtgcag ctggaggacc ctgagttcca ggccagcaac	2460
atcatgcaca gcatcaatgg ctatgtgttt gacagcctgc agctgtctgt gtgcctgcat	2520
gaggtggcct actggtacat cctgagcatt ggggcccaga ctgacttcct gtctgtgttc	2580
ttctctggct acaccttcaa gcacaagatg gtgtatgagg acaccctgac cctgttcccc	2640
ttctctgggg agactgtgtt catgagcatg gagaaccctg gcctgtggat tctgggctgc	2700
cacaactctg acttcaggaa caggggcatg actgccctgc tgaaagtctc cagctgtgac	2760
aagaacactg gggactacta tgaggacagc tatgaggaca tctctgccta cctgctgagc	2820
aagaacaatg ccattgagcc caggagcttc agccagaatc caccctcct taagcgccat	2880
cagcgcgaga tcaccaggac caccctgcag tctgaccagg aggagattga ctatgatgac	2940
accatctctg tggagatgaa gaaggaggac tttgacatct acgacgagga cgagaaccag	3000
agccccagga gcttcagaa gaagaccagg cactacttca ttgctgctgt ggagaggctg	3060
tgggactatg gcatgagcag cagcccccat gtgctgagga acagggccca gtctggctct	3120
gtgccccagt tcaagaaggt ggtgttccag gagttcactg atggcagctt caccagccc	3180
ctgtacagag gggagctgaa tgagcacctg ggcctgctgg gccctacat cagggctgag	3240
gtggaggaca acatcatggt gaccttcagg aaccaggcca gcaggcccta cagcttctac	3300
agcagcctga tcagctatga ggaggaccag aggcaggggg ctgagcccag gaagaacttt	3360
gtgaagccca atgaaaccaa gacctacttc tggaaggtgc agcaccacat ggccccacc	3420
aaggatgagt ttgactgcaa ggcctgggcc tacttctctg atgtggacct ggagaaggat	3480
gtgcactctg gcctgattgg ccccctgctg gtgtgccaca ccaacaccct gaaccctgcc	3540
catggcaggc aggtgactgt gcaggagttt gccctgttct tcaccatctt tgatgaaacc	3600
aagagctggg acttcactga gaacatggag aggaactgca gggccccctg caacatccag	3660
atggaggacc ccaccttcaa ggagaactac aggttccatg ccatcaatgg ctacatcatg	3720
gacaccctgc ctggcctggg gatggcccag gaccagagga tcaggtggta cctgctgagc	3780

atgggcagca atgagaacat ccacagcatc cacttctctg gccatgtgtt cactgtgagg	3840
aagaaggagg agtacaagat ggccctgtac aacctgtacc ctgggggtgtt tgagactgtg	3900
gagatgctgc ccagcaaggc tggcatctgg aggggtggagt gcctgattgg ggagcacctg	3960
catgctggca tgagcaccct gttcctggtg tacagcaaca agtgccagac cccctgggc	4020
atggcctctg gccacatcag ggacttccag atcactgcct ctggccagta tggccagtgg	4080
gcccccaagc tggccaggct gcactactct ggcagcatca atgcctggag caccaaggag	4140
cccttcagct ggatcaaggt ggacctgctg gccccatga tcatccatgg catcaagacc	4200
cagggggcca ggcagaagtt cagcagcctg tacatcagcc agttcatcat catgtacagc	4260
ctggatggca agaagtggca gacctacagg ggcaacagca ctggcaccct gatggtgttc	4320
tttggcaatg tggacagctc tggcatcaag cacaacatct tcaaccccc catcattgcc	4380
agatacatca ggctgcaccc caccactac agcatcagga gcaccctgag gatggagctg	4440
atgggctgtg acctgaacag ctgcagcatg cccctgggca tggagagcaa ggccatctct	4500
gatgcccaga tctactgccag cagctacttc accaakatgt ttgccacctg gagccccagc	4560
aaggccaggc tgcatctgca gggcaggagc aatgcctgga ggccccaggt caacaacccc	4620
aaggagtggc tgcaggtgga cttccagaag accatgaagg tgactggggt gaccaccag	4680
ggggtgaaga gcctgctgac cagcatgtat gtgaaggagt tcctgatcag cagcagccag	4740
gatggccacc agtggaccct gttcttccag aatggcaagg tgaaggtgtt ccagggaac	4800
caggacagct tcaccctgt ggtgaacagc ctggaccccc ccctgctgac cagatacctg	4860
aggattcacc cccagagctg ggtgcaccag attgccctga ggatggaggt gctgggctgt	4920
gaggcccagg acctgtactg aggatccaat aaaatatctt tattttcatt acatctgtgt	4980
gttggttttt tgttgttttt cctgtaacga tcgggctcga gcgcaggaac ccctagtgat	5040
ggagtggcc actccctctc tgcgcgctcg ctcgctcact gaggccgccc gggctttgcc	5100
cgggcggcct cagtgagcga gcgagcgcgc ag	5132